

ION EXCHANGE RESINS AS FUNCTIONAL EXCIPIENTS IN DRUG DELIVERY SYSTEMS

SARAVANAN.S¹, DR. S. GOPINATH AND, DR. P. SELVA KUMAR, DR. B. ANBARASAN

Department of Pharmaceutics, Sri Ramachandra Faculty of Pharmacy,
Sri Ramachandra Institute of Higher Education and Research (DU), Porur, Chennai - 116

Corresponding Author: Dr. B. Anbarasan

Assistant Professor, Department of Pharmaceutics, Sri Ramachandra Faculty of Pharmacy,
Sri Ramachandra Institute of Higher Education and Research (DU), Porur, Chennai - 116

Email: anbarasan.b@sriramachandra.edu.in

¹ **First Author:** Saravanan.S

Research Scholar, Department of Pharmaceutics, Sri Ramachandra Faculty of Pharmacy,
Sri Ramachandra Institute of Higher Education and Research (DU), Porur, Chennai - 116

Email: saravanan14393@gmail.com

Abstract: Ion exchange resins (IERS) have garnered increasing attention in pharmaceutical sciences due to their versatility, biocompatibility, and capacity to modulate drug delivery kinetics. These synthetic or natural polymeric materials, featuring ionizable functional groups, enable the reversible exchange of ions in their surrounding media, making them valuable excipients in drug delivery systems. This review explores the structural diversity and functional mechanisms of IERS, emphasizing their classification based on ionogenic groups, matrix composition, and strength of ion exchange. Special focus is given to their utility in masking unpleasant drug tastes, enhancing bioavailability, sustaining drug release, and improving patient compliance. Detailed insights into the physicochemical interactions between drugs and resins are provided, along with mechanisms governing drug loading and release. Applications across oral, topical, and ophthalmic formulations are examined, alongside discussion on factors affecting resin behavior such as pH, ionic strength, and particle morphology. Current methodologies for resin characterization and evaluation are summarized, highlighting analytical techniques used to optimize performance. Regulatory and quality considerations are also addressed, ensuring safety and consistency in pharmaceutical products. Finally, recent advances in resin-based nanotechnology, multifunctional hybrid systems, and stimuli-responsive matrices are discussed to showcase the emerging potential of IERS in precision medicine and next-generation drug delivery platforms.

Keywords: Ion exchange resins, drug delivery systems, taste masking, sustained release, child health,

How to cite this article: SARAVANAN.S¹ DR. S. GOPINATH AND DR. P. SELVA KUMAR DR. B. ANBARASAN. ION EXCHANGE RESINS AS FUNCTIONAL EXCIPIENTS IN DRUG DELIVERY SYSTEMS. Int J Drug Deliv Technol. 2026;16(83s):35-63. DOI: 10.25258/ijddt.16.83s.5.

1. Introduction: Inert or passive components are no longer considered mere pharmaceutical excipients within a formulation; they are now recognized for their functional roles in modifying the pharmacokinetics, pharmacodynamics, and stability of active pharmaceutical ingredients (APIs), earning the title “functional excipients”.^{1,2} The advancement of novel drug delivery systems has spotlighted ion exchange resins (IERS)—versatile polymeric excipients that form non-covalent, reversible ionic complexes with APIs, enabling controlled release, taste masking, and bioavailability enhancement.^{3,4}

1.1. Historical Perspective and Development: Although ion exchange principles were introduced in the 19th century, synthetic IERS were developed in the 1930s for industrial water treatment and separation processes. Their medicinal utility emerged prominently in the 1950s, with cholestyramine, a strong anion exchange resin, used for bile acid sequestration in hypercholesterolemia.⁵ Soon after, polystyrene sulfonate resins were adopted to treat hyperkalemia by exchanging potassium ions in the gut.⁶ These early successes catalyzed extensive

investigation into IERS for toxin or electrolyte sequestration, controlled drug release, taste masking, and targeted gastrointestinal delivery. Over time, advances in polymer chemistry, cross-linking, and functional group modification have enabled broad compatibility of IERS with diverse APIs and dosage forms.^{7,8}


1.2. Fundamental Properties of Ion Exchange Resins: IERS typically comprise cross-linked polymeric matrices—such as polystyrene-divinylbenzene or methacrylic acid-based backbones—bearing ionizable functional groups (e.g., sulfonic acid or tertiary amines for cationic or anionic exchange, respectively). Their mechanism—based on reversible electrostatic attraction—permits API binding without chemical modification, governed by ion exchange equilibria and resin characteristics like ion exchange capacity (IEC), particle size and surface area, porosity and swelling behavior, diffusion rates, and thermal/chemical stability.^{3,9}

1.3. Pharmaceutical Relevance and Applications:

IERs are prized in drug delivery due to their adaptability across APIs and dosage forms. Drug-resin complexes (resinates) regulate drug release and safeguard against environmental stressors. Particularly notable is taste masking, crucial for improving compliance in children and the elderly. Weak cation exchange resins such as Indion 234 or Amberlite IRP64 are widely used for bitter drugs like ondansetron and ciprofloxacin—effectively masking taste until release in gastric environments.^{10,11} IERs also support sustained-release formulations, exemplified by hydrocodone-polistirex and methylphenidate resin complexes (e.g., Metadate CD®, Quillivant XR®) designed for once-daily dosing and consistent therapeutic levels.¹²

Moreover, pH- and ion-dependent release profiles of IERs allow for site-specific targeting, such as selective drug release in the colon—beneficial for conditions like inflammatory bowel disease or colorectal cancer.¹³ They also enhance drug stability, protecting labile APIs (e.g., peptides, enzymes) from moisture, oxidation, or enzymatic degradation via resin entrapment. Emerging research explores IER-based microspheres and nanocomposites to improve the oral bioavailability of challenging molecules like insulin, curcumin, and probiotics.^{14,15}

1.4. Role in Patient-Centric and Regulatory-Oriented Formulations: With the shift toward patient-centered formulation design, IERs facilitate development of age-friendly dosage forms such as orally disintegrating tablets (ODTs), oral films, and palatable suspensions—enhanced by taste masking and flexible dosing. In pediatric and geriatric populations, products featuring weak cation exchange resins deliver both palatability and stable dosing (e.g., liquid fexofenadine or loratadine).¹⁶ From a regulatory standpoint, many IERs (Amberlite™, Dowex®, Indion®, Tulsion®, Kyron™) are listed in pharmacopeias (USP, Ph. Eur., JP) as pharmaceutical-grade with GRAS status. Their use in FDA-approved products is supported by stringent quality controls—covering parameters such as particle size, swelling index, moisture, and heavy metal levels. However, standardized in vitro–in vivo correlation (IVIVC) models remain limited; factors like ionic strength, diet, individual GI physiology, and competing electrolytes complicate generalized dissolution testing.^{17,18}



2. Classification of Ion Exchange Resins: Ion exchange resins (IERs) are cross-linked polymers that possess functional groups and high molecular weight, which enable the exchange of ions with surrounding media. The pharmacological utility of these substances is dependent on their physicochemical traits, which include drug loading capacity, release profile, biocompatibility, and stability. Rational selection and formulation design are commonly supported by the classification of IERs based on various criteria, including the type of individual ion exchanged, chemical composition, cross-linking degree, origin, and functional performance. Understanding these classifications is crucial in determining how drug delivery systems can be tailored to meet specific therapeutic and patient-centric needs.^{19,20}

2.1. Classification based on the nature of Exchangeable Ions: The most basic classification directly pertains to the type of interaction between drug and resin.²¹

2.1.1. Cation Exchange Resins (CERs): CERs are polymers that have negative groups, allowing for the exchange of positively charged ions from surrounding media. These resins play a major role in the production of pharmaceuticals by binding on other cationic drugs, altering their release, and improving stability or palatability.^{22,23} They are indispensable in the formulation of oral, buccal, and parenteral dosage forms due to their versatile chemistry and well-established safety profiles.²⁴

2.1.1.1. Structural Characteristics: A cross-linked polymer matrix, typically based on

- Polystyrene-divinylbenzene (PS-DVB) copolymers,
- Methacrylic acid derivatives, providing additional hydrophilicity and flexibility.²⁵

Cation exchange is facilitated by the following functional groups: The acidity of sulfonic acid (-SO₃H) is high as it remains ionized across a wide range of pH levels. Carboxylic acid (-COOH) dissociates primarily at pH >5 due to its weak acidic

properties. The porous resin matrix contains a multitude of these groups, which facilitates electrostatic interactions with cationic drugs.²⁶

2.1.1.2. Mechanism of Ion Exchange: In the ion exchange mechanism, there are several cations on the resin that cationic drug molecules can exchange, and these can undergo reversible displacement. It usually happens in a liquid state where the drug is:

1. Protonated and dissolved state (if weakly basic).
2. Mixed with the resin to facilitate ionic binding.
3. Filtered and dried, the mixture (resin complex) of drugs is produced.

The replacement of the bound drug with endogenous counterions in physiological environments, such as Na^+ or K^+ in saliva or gastrointestinal fluid, results in controlled drug release through ion exchange.²⁷

2.1.1.3. Pharmaceutical Applications: CERs are widely used in many therapeutic areas due to their versatility. Key applications include:

Taste Masking of Bitter Drugs: Chlorpheniramine, dextromethorphan, and ondansetron are examples of basic drugs that have intense bitterness, which interfere with patient compliance. Why is this so? The interaction between these drugs and taste receptors is reduced when they form complexes with CER. Drug release is reduced in the neutral pH of saliva and resumed in gastric pH, making formulations more palatable.^{28,29}

Sustained and Controlled Drug Release: When produced in tablets, suspensions, or multiparticulates, CERs act as a rate-controlling matrix and are released in a controlled manner. By optimizing ion exchange kinetics and using coating technologies like ethylcellulose or Eudragit, the duration between 12–24 hours can be extended for drug release. Tussionex® employs polystyrene sulfonate resin as a barrier to limit the release of hydrocodone and chlorpheniramine.²⁷

Stabilization of Sensitive APIs: Drugs can be protected against hydrolysis, oxidation, or photodegrading by the microenvironment within the resin matrix. This helps to stabilize sensitive APIs. Especially useful for highly unstable free-form APIs such as levothyroxine, ciprofloxacin, and the neuroprotective drug epinephrine.³⁰

Ion Removal and Detoxification Therapies: CER substances, such as sodium polystyrene sulfonate (Kayexalate®), are used to attach excess potassium by exchanging Na^+ for K^+ in the colon in cases of hyperkalemia. These resins serve as Pharmaceutical and therapeutic applications.^{28,29}

Modulation of Drug Solubility and Absorption: The solubility and absorption of poorly water-soluble drugs can be improved by CERs through ion exchange-mediated dissolution, particularly in wet granulations or suspensions. The reduction of dose

dumping could lead to improved bioavailability through this method.³¹

2.1.1.4. Selection Considerations in Formulation: Several formulation parameters are essential in selecting the correct CER: Optimal binding of the drug occurs when it is ionized, and its pK_a remains constant. Resin particles' size and porosity are important factors in achieving better binding, but their filtering is more challenging. The density of cross-linking influences both diffusion and swelling properties in resins. Considering the resin-to-drug ratio, it is important to consider the loading efficiency and release profile. Efficiently utilizing raw materials and manufacturing techniques.³²

2.1.1.5. Limitations and Challenges: While CERs are commonly used, they have certain restrictions: In low ionic strength environments, such as fasting, drug-resin complexes may exhibit variable bioavailability. In vitro–in vivo correlation (IVIVC) can be challenging to determine due to the presence or absence of variable counterion concentrations. Particle size distribution and viscosity control are essential for the stability of suspensions that contain CER. Despite this, the development of resin functionalization, coating technologies, and nanostructuring is gradually resolving numerous issues, expanding the role of CERs in modern drug delivery.^{33,34}

2.1.2. Anion Exchange Resins (AERs): The exchange of negatively charged ions from the environment is made possible by synthetic polymeric materials that are cross-linked with positively charged functional groups, known as anion exchange resins (AERs). Various pharmaceutical uses have been identified for these resins, such as their ability to attach anionic drugs, removal of toxic anions, and modulation of drug release in different dosage forms. Both formulation development and therapeutic interventions benefit from their flexible surface chemistry and strong ion-binding affinity.^{30,35}

2.1.2.1. Structural Characteristics: AERs are typically constructed from polystyrene-divinylbenzene (PS-DVB) or polyacrylate matrices, and they are functionalized with one of the following cationic groups: Quaternary ammonium ($-\text{N}^+(\text{CH}_3)_3$) is one of the most basic groups, and it remains ionized across a broad range of pH levels. Basic elements, like primary or secondary amines ($-\text{NH}_2 + \text{OH}_3 + \text{DE}$), which are predominantly present in neutral pH ranges, can be weakly basic groups. By adjusting the resin's cross-linking density, one can achieve the desired formulation performance that meets specific requirements, including swelling behavior and drug-resin binding kinetics.³⁶

2.1.2.2. Mechanism of Ion Exchange: The mechanism of AERs involves the substitution of preloaded anions (e.g., Cl^- , OH^-) with biological ions or anionic drug

molecules in aqueous environments. The process typically involves: 1. dissolving the anionic drug in an appropriate solution while the resin is suspended. 2. Including it in the AER, permitting electrostatic binding. 3. The process of washing and drying the resulting drug-resin complex (resinate). The release of the bound drug is initiated by a clash of physiological anions (e.g., Cl^- , bicarbonate) upon administration. This occurs in vivo.³⁷

2.1.2.3. Pharmaceutical Applications: Anion exchange resins are now widely used in various therapeutic categories due to their capacity to bind acidic drugs, regulate ionic acidity, and enable site-specific delivery. Key applications include:

Binding and Sequestration of Endogenous Anions: The sequestration of endogenous anions and the binding of bile acids are inhibited by AERs like cholestyramine resin USP, which can be used to treat hypercholesterolemia. The elimination of excess phosphate or toxins is accomplished through comparable techniques in cases of renal failure.^{30,31}

Controlled and Sustained Release of Acidic Drugs: The release of acidic drugs, such as aspirin, diclofenac, and furosemide, can be controlled by loading them onto AERs for pH-independent release. The gradual dissociation of drugs is facilitated by anions being removed from the GI tract, which allows for once-daily or delayed-release oral systems.^{36,37}

Taste Masking of Acidic APIs: AERs can mask the taste of acidic compounds by preventing their immediate interaction with taste receptors in the mouth, which may result from an increased concentration of tartar or other flavors. This is especially useful in chewable tablets, lozenges, and oral suspensions, which are used in pediatric and geriatric formulations.³⁸

Enhanced Drug Stability: AERs can act as a buffer for acid-responsive compounds by protecting them from acid hydrolysis, photodegradation, and oxidation.³⁹

Site-Specific Delivery in the GI Tract: By incorporating formulations into solid dispersions or bead-based systems, durability and shelf life are enhanced. AERs can be designed to release drugs at specific pH levels or in response to local ion concentrations in the GI Tract. They are appropriate for use with targeted delivery, enteric formulations, or locally acting anti-inflammatory drugs in the colon.³⁶

2.1.2.4. Selection and Optimization Criteria: The selection of an appropriate AER for pharmaceutical use is guided by: pKa of the drug: AERs are suitable for drugs ionized as anions at physiological pH, Type of resin (strong vs. weak base): Determines pH range for efficient binding and release, Particle size and porosity: Influences drug loading efficiency and release kinetics, Counterion effects: The nature of

exchangeable ions on the resin (e.g., Cl^- vs. OH^-) can affect drug stability and complexation.

Commercially available pharmaceutical-grade AERs include: A Cholestyramine resin, which is a basic and quaternary ammonium substance. Amberlite™ IRA-400 and IRA-67. Duolite AP series resins. FDA's Inactive Ingredient Database lists these resin compounds for approved oral and topical formulations.³⁹

2.1.2.5. Challenges and Considerations: Despite their numerous formulation benefits, AERs are not completely free of limitations. In low-ion settings (such as fasting), drug release is not always predictable. Nonspecific ion binding may interfere with the absorption of co-administered nutrients or drugs. The integrity of the tablet and stability of the suspension may be compromised due to hygroscopicity and swelling properties. To address these challenges, AER-based systems frequently incorporate functional coatings, such as ethylcellulose and Eudragit. Utilizing a hydrophilic polymer or matrix combination. Targeted release profiles can be achieved through the use of layers or multiparticulate designs. AERs are anticipated to aid in precision medicine and personalized therapeutics. With growing interest in ion-exchange-assisted drug delivery, particularly in combination with mucoadhesive systems, floating drug delivery, and nanoparticle platforms, AERs are poised to support future advances in precision medicine and personalized therapeutics.⁴⁰

2.1.3. Ampholytic (Zwitterionic) Resins: These are called ampholytic ion exchange resins, also known as zwitterionic resins, and they contain the acid (anionic) and the base (cationic), on the same polymeric matrix. Both positively and negatively charged species can interact with these dual-functional materials, depending on the pH level and ionic conditions in their surroundings. Their structure is reminiscent of that of zwitterions in biological systems, which allows for the exchange of two ion beams between them, making them highly adaptable.⁴⁰

2.1.3.1. Structural Characteristics: It is common to combine the two, to manufacture ampholytic resins: Sulfonic acid ($-\text{SO}_3\text{H}$), carboxylic acid ($-\text{COOH}$), (or) phosphonic acid (PO_3H_2) and anionic groups, respectively, primary, secondary, or quaternary amines ($-\text{NH}_2$, $-\text{NR}_3^+$). Grafting these functional groups onto a polystyrene-divinylbenzene (PS-DVB) backbone or polyacrylic Polymer creates essentially cross-linked, three-dimensional matrix that allows for reversible ionic interactions.⁴⁰⁻⁴³

2.1.3.2. Mechanism of Ion Exchange: The ion exchange behavior of ampholytic resins is highly dependent on pH. Anions are primarily used as anion exchangers in the resin due to their tendency to protonate basic groups at acidic pH. At alkaline pH,

the acidic groups are deprotonated, and the resin acts as a cation exchanger. In neutral to mildly buffered environments, both ion exchange functions can be active at the same time, allowing for simultaneous binding of anionic and cationic species.⁴⁴⁻⁴⁶ Pharmaceutical systems can benefit from this dual nature, which necessitates the complex formation, stabilization, or selective release of multiple ions or amphoteric drugs.

2.1.3.3. Pharmaceutical Relevance and Potential Applications: Ampholytic resins hold significant promise in various emerging fields, but their use in marketed pharmaceutical products is still limited by conventional monoionic resin techniques: The acidic and basic group structure of drugs like ciprofloxacin, norfloxacin, and tetracycline is evident in their complexation.⁴⁷⁻⁴⁹ The formation of stable complexes between ampholytic resins and these molecules under specific conditions may result in improved solubility, stability, and bioavailability. pH-modulated delivery systems can incorporate ampholytic resins into controllable release systems due to their ion exchange profile being in the same pH range.⁵⁰ Drug release can be directed to specific areas of the gastrointestinal tract, such as the colon or stomach, where pH changes occur due to these systems.⁵¹ By creating zwitterionic environments, ampholytic resins can provide a stabilizing microenvironment for labile biomolecules such as enzymes or peptides, thus protecting them from hydrolysis, (i.e. By enabling the simultaneous binding of two distinct APIs (one cationic and one anionic), drug combinations can be delivered in combination in a single dosage form, which is driving an increasing interest in personalized and fixed-dose combination therapies.⁵²⁻⁵³ This technology is also known as a dual dual-function platform. In applications that aim to eliminate excess ions from the GIT, such as kidney stones, ampholytic resins can serve as effective ionic scavenging agents. This feature is beneficial in treating renal disease and other diseases.⁵⁴ Their capacity to both buffer and exchange can increase their efficacy in detoxification-based treatments.⁵⁵

2.1.3.4. Challenges and Limitations: Despite their potential, ampholytic resins face several obstacles. Batch variability may occur during complex synthesis and functional group balancing.⁵⁶ Their ion exchange behavior is more difficult to model and predict than that of monoionic resins.⁵⁷ A significant number of ampholytic materials possess scant toxicity and pharmacokinetic information, which could result in regulatory challenges.⁵⁸ As material science advances, especially in polymer engineering and nanotechnology, it is expected that more pharmaceutically acceptable ampholytic resins will

emerge, providing new platforms for multi-functional drug delivery systems.⁵⁹⁻⁶⁰

2.2. Functional group strength is used to classify resins. Apart from cationic, anionic, or ampholytic nature of the exchanging ions, they can also be classified by strength of their ionizable functional groups, which is one of many properties of an ion exchange resin that determines its binding affinity, its pH, and release kinetics. This classification holds great importance in the context of resin-drug interactions in pharmaceuticals, where the physiological pH range and drug ionization profiles are directly linked. Generally, ion exchange resins are classified into the following groups:

1. Strong acid cation (SAC) resins.
2. Weak acid cation (WAC) resins.
3. Strong base anion (SBA) resins.
4. Weak base anion (WBA) resins.

Here are the distinct physicochemical and functional characteristics of each class.

2.2.1. Strong Acid Cation (SAC) Resins: The typical structure of strong acid cation resins is composed of cross-linked polystyrene matrix, which contains sulfonic acid (-SO₃H) functional groups. The groups remain ionized and can exchange cations at nearly constant pH for many years.⁶¹⁻⁶²

Key Properties: In environments with high acidity, the ionization process remains intact. H⁺, Na⁺, K⁺, Ca²⁺, Mg²⁺ are exchangeable ions that can be countered. Strengthened thermal and chemical stability. Fast exchange kinetics.⁶¹⁻⁶²

Pharmaceutical Applications: The taste masking and prolonged release of basic drugs like dextromethorphan and diphenhydramine. Sodium polystyrene sulfonate is one example of detoxification resins used to aid in potassium binding in hyperkalemia. Used in oral suspensions, chewable tablets and other substances for efficient drug loading and controlled delivery. Examples, Amberlite IRP-69, Tulsion 335, and Kyron T-134.^{61,65}

2.2.2. Weak Acid Cation (WAC) Resins: Since carboxylic acid (-COOH) groups ionize at pH > 5, WAC resins have a high degree of sensitivity to pH. These resins are usually composed of polyacrylic acid derivatives, which give rise to more hydrophilic and swellable matrix configurations.⁶⁴⁻⁶⁶

Key Properties: Can be achieved in neutral to slightly alkaline conditions. In comparison to SAC resins, their ion exchange capacity is smaller. Increased swelling in liquids.⁶⁴⁻⁶⁶

Pharmaceutical Applications: Drugs can be metabolized and delivered to the colon through pH-sensitive. Selective binding of weakly basic drugs. In acidic environments, early release of drugs is reduced through this process. Examples, Amberlite IRC-50, Tulsion 343.⁶⁶

2.2.3. Strong Base Anion (SBA) Resins: SBA resins utilize quaternary ammonium groups ($-N^+(CH_3)_3$) that remain ionized throughout a broad pH range, facilitating the exchange of anions such as Cl^- , OH^- , NO_3^- , and SO_4^{2-} .^{67,68}

Key Properties: Strong and weak acid anions exhibit high binding affinity. Stable across pH 1–10. Long-lasting use in acidic and neutral conditions.⁶⁷⁻⁶⁸

Pharmaceutical Applications: Using cholestyramine resin, which is an example of a bile acid sequestrant, in hypercholesterolemia. Complexation of acidic drugs to achieve controlled release. Ion scavenging in electrolyte balance or detoxification formulations is encouraged. Examples, Amberlite IRA-400 and Duolite A-1010D.⁶⁷

2.2.4. Weak Base Anion (WBA) Resins: These resins can be functionalized with different types of primary, secondary, or tertiary amines, which only react with them when they are under acidic to neutral pH (pH 7). Thus, their anion exchange capacity significantly decreases in alkaline conditions.^{69,70}

Key Properties: effective in mild acids. It can degrade under strong alkali conditions or oxidize easily. SBA resins have a higher exchange capacity than WBA.^{69,70}

Pharmaceutical Applications: The upper GI can be targeted by the selective administration of acidic drugs. Might work in mucoadhesive or pH-triggered delivery systems. While not widely available, it has the potential to be used for antiviral and antibacterial coatings.^{69,70}

2.3. Classification Based on Matrix Composition: Depending on the polymeric matrix, which determines key physicochemical properties such as mechanical strength, porosity, hydrophilicity, and biocompatibility. Pharmaceutical formulations are affected by these properties in terms of their impact on drug loading efficiency, release kinetics (in an automated process), stability, and processability.^{71,72} Three primary classifications exist in matrix composition:

1. Polystyrene-Divinylbenzene (PS-DVB) Based Resins.
2. Polyacrylic or Methylated Acid-Based Resins
3. Cellulose and other natural polymer resins.

2.3.1. Polystyrene-Divinylbenzene (PS-DVB) Based Resins: Synthetic ion exchange resins are the most commonly used in the pharmaceutical industry. A hydrophobic, cross-linked polystyrene backbone is present in the materials, and divinylbenzene (DVB) serves as a cross-linker to regulate porosity and rigidity.⁶¹⁻⁶⁵

Key Features: High levels of mechanical and chemical stability. Available in gel-type (non-porous) and macroporous forms. Good ion exchange capacity for

both anion and cation. High DVB content variants exhibit low water absorption.⁶¹⁻⁶⁵

Pharmaceutical Applications: Highly utilized in taste masking, sustained release, and targeting ion extrusion (e.g. Tussionex®, Kayexelide). Common in strong acid cation resins (e.g., sulfonated PS-DVB) and strong base anion resins (e.g., quaternized PS-DVB), Examples, Amberlite IRP-69, Tulsion 335, Duolite A-101D, Cholestyramine.⁶¹⁻⁶⁵

2.3.2. Polyacrylic and Methacrylic Acid Based Resins: These resins consist of polyacrylic acid or polymethacrylate matrices, which are sometimes cross-linked with DVB or other materials. Their hydrophilic characteristics make them ideal for controlled drug delivery systems, providing excellent swelling and diffusion capabilities.^{66,67}

Key Features: More appropriate for weak acid cation or weak base anion exchange properties. Enhanced biocompatibility and mucoadhesion. Increased water absorption and swelling in aqueous settings. Superior drug diffusivity but reduced mechanical strength compared to PS-DVB.^{66,67}

Pharmaceutical Applications: Employed for prolonged and pH-regulated medication release. Effective in colonic delivery systems or oral adhesive formulations. It can improve the solubility and permeability of drugs that have low solubility. **Examples:** Tulsion 343, Kyron T-134, Amberlite IRP-64.^{66,67}

2.3.3 Cellulose-Based and Natural Polymer Resins: These resins, which are either semi-synthetic or of natural origin, are obtained from cellulose, starch, or other plant-derived materials and are modified to include ionizable groups. Although not as prevalent as synthetic resins, they are attracting attention for their biodegradability, sustainability, and user-friendly traits.^{68,69}

Key Features: Biocompatible and biodegradable. Moderate ion exchange capacity. Environmentally friendly and potentially GRAS-listed. Swellable and gel-forming.⁶⁹

Pharmaceutical Applications: Explored in gastroretentive, buccal, and colon-targeted systems. Potential use in natural excipient matrices for pediatric and geriatric dosage forms. May serve as carriers in nanoparticulate drug delivery. **Examples,** Carboxymethyl cellulose-based resins, cationic starch derivatives.^{68,69}

Table 1: Classification of Ion Exchange Resins with Commercial Examples

Classification Criteria	Type of Resin	Functional Groups	Examples (Commercial)	Key Pharmaceutical Applications
Based on Ionic Nature	Cation Exchange Resins (CERs)	Sulfonic acid (-SO ₃ H), Carboxylic acid (-COOH)	Amberlite IRP-69, Indion 234, Dowex 50, Amberlite IR-120, Indion 204	Taste masking (e.g., pseudoephedrine), ^{61,62} sustained release, ⁶¹⁻⁶² API purification ⁶³
	Anion Exchange Resins (AERs)	Quaternary ammonium (-N+(CH ₃) ₃), Tertiary amine (-NH(CH ₃) ₂)	Cholestyramine (Duolite A143), Amberlite IRA-400, Amberlite IRA-402, Indion 264	Cholesterol-lowering (bile acid sequestration), ^{67,68} API stabilization, ⁶⁷ controlled release ⁶⁸
	Ampholytic Resins	Both cationic and anionic groups	Amphoteric cellulose derivatives, ampholytic methacrylate copolymers	Selective ion removal, ⁶⁹ sustained release, ⁶⁹ pH-responsive delivery ⁶⁹
Based on Functional Group Strength	Strong Acid Cation (SAC)	Sulfonic acid (-SO ₃ H)	Amberlite IRP-69, Dowex 50WX4	Drug taste masking, ⁶¹ immediate ion exchange ^{61,62}
	Weak Acid Cation (WAC)	Carboxylic acid (-COOH)	Amberlite IRC-50, Indion 234	pH-dependent release, ⁶⁴⁻⁶⁶

Classification Criteria	Type of Resin	Functional Groups	Examples (Commercial)	Key Pharmaceutical Applications
				GI targeting ^{64,66}
	Strong Base Anion (SBA)	Quaternary ammonium (-N+(CH ₃) ₃)	Amberlite IRA-400, Cholestyramine	Bile acid sequestration, ^{67,68} drug stabilization ^{67,68}
	Weak Base Anion (WBA)	Tertiary amine (-NH(CH ₃) ₂)	Amberlite IRA-93, Duolite A7	Controlled release in acidic media ⁶⁹⁻⁷⁰
Based on Matrix Composition	Styrene-Divinylbenzene (S-DVB)	Sulfonic acid, quaternary ammonium	Dowex series, Amberlite series, Indion series	High mechanical strength, ⁶¹ wide pH range ^{61,65}
	Acrylic/Methacrylic	Carboxylic acid, quaternary ammonium	Fractogel® EMD SO ₃ -, Fractogel® EMD DEAE	High capacity for large molecules, ⁶⁶ protein purification ^{66,67}
	Cellulose-Based	Carboxymethyl, DEAE	DEAE-Sephadex A-25, CM-Sephadex C-25	Biocompatible drug carriers, ⁶⁸ mucosal adhesion ^{68,69}
	Chelating Resins	Iminodiacetic acid, other chelators	Chelex 100, Dowex A-1	Metal ion removal from formulations ^{71,72}
	Pediatric Taste-	Various functional groups	TasteGuard-WC, Indion 204,	Oral syrups, chewable tablets ⁷¹

ION EXCHANGE RESINS AS FUNCTIONAL EXCIPIENTS IN DRUG DELIVERY SYSTEMS

Classification Criteria	Type of Resin	Functional Groups	Examples (Commercial)	Key Pharmaceutical Applications
	Masking Resins		Amberlite IRP-64	
	High-Throughput Chromatography Resins	Various functional groups	Fractogel® TMAE, Fractogel® SO ₃	API purification ⁶⁶ , peptide purification ^{66,67}
Specialty Pharma Resins	Metal Ion-Scavenging Resins	Iminodiacetic acid, thiol groups	Chelex, Purolite S930	Removal of catalyst residues in API manufacturing ^{71,72}

Table 2: Summary of Ion Exchange Resin Classifications and Their Key Attributes

Classification Criterion	Type	Functional Groups	Ion Exchange Capacity	Key Applications in Drug Delivery	Advantages	Limitations
Based on Ionic Charge	Cation Exchange Resins (CERs)	Sulfonic acid (-SO ₃ H), Carboxylic acid (-COOH)	High (0.5–6 meq/g)	Taste masking, sustained release of basic drugs, stabilization of alkaline drugs ^{61,62}	Strong binding to cationic drugs, good thermal stability ^{61,62}	Poor binding with neutral or weakly basic drugs ⁶³
	Anion Exchange	Quaternary ammonium	Moderate to high	Controlled release	Strong affinity for	Sensitive to pH, lower

Classification Criterion	Type	Functional Groups	Ion Exchange Capacity	Key Applications in Drug Delivery	Advantages	Limitations
	Resins (AERs)	Ium (-NR ₃ ⁺), Tertiary amine (-NR ₂ H ⁺)	(0.4–5 meq/g)	of acidic drugs, removal of anionic impurities ^{67,68}	acidic drugs, tunable release ^{67,8}	stability in acidic conditions ⁶⁷⁻⁶⁸
	Amphoteric Resins	Both cationic and anionic functional groups	Variable (0.2–3 meq/g)	Simultaneous binding of acidic and basic drugs, multi-drug delivery ⁶⁹	Versatile drug binding ⁶⁹	Complex release control, high cost ⁶⁹
Based on Functional Group Strength	Strong Acid Cation (SAC)	Sulfonic acid	High, stable over pH 0–14	Controlled release in gastric and intestinal fluids ^{61,62}	Stable in wide pH range ^{61,62}	Possible drug degradation under extreme pH ⁶¹
	Weak Acid Cation (WAC)	Carboxylic acid	pH dependent	Taste masking, delayed release ^{64,66}	Mild conditions, biodegradable ^{64,66}	Lower exchange at high pH ^{64,66}

ION EXCHANGE RESINS AS FUNCTIONAL EXCIPIENTS IN DRUG DELIVERY SYSTEMS

Classification Criterion	Type	Functional Groups	Ion Exchange Capacity	Key Applications in Drug Delivery	Advantages	Limitations
	Strong Base Anion (SBA)	Quaternary ammonium	Stable over pH 0–14	Controlled release of acidic drugs ^{67,68}	High exchange capacity ^{67,68}	Sensitive to oxidative degradation ^{67,68}
	Weak Base Anion (WBA)	Tertiary amine	pH dependent	Delayed release of acidic drugs ^{69,70}	Good selectivity ^{69,70}	Low stability in strong acids ^{69,70}
Based on Matrix Type	Gel-type Resins	Functional groups within hydrated polymer matrix	Mode rate	Rapid ion exchange, taste masking ^{61,65}	Fast drug loading ^{61,65}	Limited mechanical strength ^{61,65}
	Macroporous Resins	Functional groups in large pore structure	High	Sustained release, high-capacity drug adsorption ^{61,65}	High mechanical stability, good swelling control ^{61,65}	Higher cost ^{61,65}
	Microbead Resins	Small spherical particles	Variable	Oral suspensions, pediatric	Easy processing, good flow ^{66,71}	Lower exchange in viscous

Classification Criterion	Type	Functional Groups	Ion Exchange Capacity	Key Applications in Drug Delivery	Advantages	Limitations
				formulations ^{66,71}		media ^{66,71}
Based on Source	Synthetic Polymer Resins	Polystyrene, polyacrylic derivatives	High	All types of drug delivery ^{61,67}	High capacity, consistent quality ^{61,67}	Non-biodegradable ^{61,67}
	Natural Polymer Resins	Cellulose, chitosan	Mode rate	Mucoadhesive systems, hydrophilic drug matrices ^{68,69}	Biodegradable, biocompatible ^{68,69}	Lower capacity, batch variation ^{68,69}

3. Mechanism of Drug Loading and Release from Ion Exchange Resins:

Ion exchange resins (IERS) act as active agents that engage with drug molecules of opposite charge via reversible electrostatic forces, creating drug-resinate complexes. These complexes act as functional excipients, facilitating controlled drug release, taste masking, targeted delivery to specific sites, and stabilization of unstable drugs.^{61,62,67} The effectiveness of drug loading and later release is influenced by a variety of factors such as resin type, ionic strength, pH, degree of cross-linking, drug-resin affinity, and the presence of competing ions in the surrounding environment.^{61,64,66}

The procedure generally consists of two interconnected stages:

Drug Loading – in which the drug is attached to the resin matrix through ionic bonds.

Release of drugs – initiated by ion-exchange reactions under physiological conditions.^{61,62,64} Each phase operates through well-characterized physicochemical mechanisms, which are elaborated below.

3.1 Drug Loading onto Ion Exchange Resins

3.1.1 Principle of Ion Exchange: Drug loading occurs when an ionized drug molecule replaces an exchangeable counterion (such as H⁺, Na⁺, or Cl⁻) present on the functional group of the resin.^{61,63} This process is based on stoichiometric exchange and follows a mass action law, wherein a high concentration of drug ions in solution drives the equilibrium toward complexation.

General Reaction:

For a cationic drug (D⁺) and a cation exchange resin (R-SO₃⁻Na⁺):

$$\text{R-SO}_3^-\text{Na}^+ + \text{D}^+ \rightleftharpoons \text{R-SO}_3^-\text{D}^+ + \text{Na}^+ \quad 61,62$$

Similarly, for an anionic drug (A⁻) and an anion exchange resin (R-N⁺(CH₃)₃Cl⁻):

$$\text{R-N}^+(\text{CH}_3)_3\text{Cl}^- + \text{A}^- \rightleftharpoons \text{R-N}^+(\text{CH}_3)_3\text{A}^- + \text{Cl}^- \quad 67,68$$

3.1.2 Methods of Drug Loading: Several techniques are employed to load drugs onto resins,^{61,62,66} depending on their physicochemical properties:

Batch Method: Drug and resin are mixed in aqueous or hydroalcoholic solution under constant agitation until equilibrium is reached.^{61,62}

Column Method: Resin is packed into a column and drug solution is passed through, allowing ion exchange as the drug percolates.^{66,67}

Kneading or Suspension Methods: Particularly for poorly soluble drugs, where drug-resin mixtures are ground together with a minimal solvent.^{69,70}

Key parameters influencing loading include: pH of medium (to ensure ionization of the drug). Resin-to-drug ratio. Contact time and agitation speed. Swelling behavior of resin matrix.^{61,64,66,69}

3.1.3 Factors Affecting Drug Loading

Ionization degree of drug: Only ionized species can interact with the resin.^{61,62}

Counterion type and concentration: Competing ions in solution (e.g., Na⁺, H⁺) can displace or inhibit drug binding.^{64,66}

Cross-linking density of the resin: Higher cross-linking decreases swelling, reducing accessibility to internal exchange sites.^{61,62}

Drug molecular size and polarity: Larger or highly hydrophobic drugs may have limited access to exchange sites.^{69,70}

3.2 Methods of Drug Loading: The efficiency of drug loading onto ion exchange resins depends not only on the chemical nature of the drug and resin, but also on the choice of loading technique. Widely used in taste-masked chewable tablets, suspensions, and oral dispersible formulations.^{61,62} The method selected directly influences drug-resin complex stability, loading efficiency, and batch reproducibility. Several commonly used methods are described below:

3.2.1 Batch Method (Equilibrium Binding Method):

This is the most widely adopted and experimentally straightforward technique. In this method, a known amount of resin is suspended in a solution containing the drug at a defined concentration. The mixture is stirred continuously for a predetermined time, allowing the drug to bind to the ion exchange sites until equilibrium is achieved. Batch method is simple setup, easy scale-up, high loading efficiency when optimized. Key variables are: pH of the medium (affecting drug ionization), Resin-to-drug ratio (affecting stoichiometry), Ionic strength, and presence of competing ions (e.g., Na⁺, Cl⁻), Temperature and agitation speed.

Methodology:

1. **Preparation of Drug Solution:** Drug dissolved in a suitable aqueous or hydroalcoholic medium and pH adjusted to ensure the drug remains in its ionized form (typically pH 3–8 for weak bases or acids).
2. **Resin Pre-treatment:** Resin pre-washed with deionized water or counter-ion solution (e.g., 0.1 N NaCl or 0.1 N HCl) to exchange unwanted ions and swell the resin. Decant and repeated until neutral pH is achieved.
3. **Drug-Resin Mixing:** Known quantity of resin dispersed with the drug solution in a stoppered conical flask or jacketed reactor and stir using a magnetic stirrer or orbital shaker for 1–24 hours depending on equilibrium kinetics.
4. **Separation and washing:** Resinate centrifuged or filtered and washed multiple

times with deionized water to remove surface-bound drug.

5. **Drying and Evaluation:** Dried under vacuum, at 40–60 °C (depending on drug stability), until constant weight. Evaluated drug content via UV spectroscopy or HPLC after acid/base extraction.

Key Control Parameters: Resin-to-drug ratio (e.g., 1:1 to 1:4 w/w), Contact time (minimum 4–6 hours for equilibrium), pH maintenance (essential for drug ionization), Temperature (room temp or slightly elevated to improve kinetics).^{61,62,64,66}

3.2.2 Column Method (Percolation Technique): In this method, the ion exchange resin is packed into a glass or plastic column, and the drug solution is allowed to percolate slowly through it. As the solution flows, drug molecules are exchanged with counterions on the resin surface and within its pores. This method is particularly useful when drug-resin interactions must be highly controlled and consistent, such as in large-scale or GMP-compliant manufacturing.^{66,67} Continuous processing and purification promote uniform drug loading across the resin bed.

Key Control Parameters: Flow rate of the drug solution, Column height and resin bed density, Contact time and backpressure.^{66,67}

Methodology:

1. **Column Preparation:** Pre-swollen resin filled in clean glass or plastic column and place a fine frit at the bottom to avoid loss of resin beads.
2. **Drug Solution Preparation:** Drug dissolved in de-aerated water or buffer at a suitable pH.
3. **Percolation Process:** Drug solution passed slowly (e.g., 0.5–2 mL/min) through the column using a peristaltic pump and effluent collected to monitor the drug depletion.
4. **Washing and Elution:** Washed with deionized water to remove unbound drug. Optionally, elute a small portion with counter-ion (e.g., 0.1 N NaCl) to assess binding efficiency.
5. **Drying and Storage:** Drying of drug loaded resinate under vacuum or mild heat.

Key Control Parameters: Flow rate (slower enhances binding), Bed height and particle size (affect contact time), Multiple passes or recycling may be used for complete loading.^{66,67}

3.2.3 Kneading Method: Commonly used for taste masking in chewable tablets, lozenges, or buccal patches. The kneading method involves the physical mixing of a resin and drug in the presence of a minimal amount of solvent (usually water, ethanol, or hydroalcoholic mixtures) to form a semi-solid paste. The mixture is kneaded (trituated) thoroughly to ensure intimate contact, followed by drying. This method suitable for poorly water-soluble drugs or

moisture-sensitive APIs and useful in preparing taste-masked oral dispersions and chewable formulations. This method result in incomplete loading if not adequately hydrated and requires post-processing to remove unbound drug.

Methodology:

1. **Pre-wet Resin:** Resin mixed with small amount of water or hydroalcoholic solvent to initiate swelling.
2. **Drug Addition:** Powdered drug added into the pre-wet resin and triturate using a mortar and pestle or mechanical kneader.
3. **Kneading Process:** Continued kneading until a uniform paste forms.
4. **Drying:** Dried in a vacuum oven or fluid bed dryer at 40–50 °C.
5. **Sizing and Storage:** Pulverize and sieve the dried mass for uniform particle size distribution.

Key Control Parameters: Solvent volume (enough to form paste, not slurry), Kneading time and pressure (affects diffusion of drug), Drug solubility in kneading medium.^{69,70}

3.2.4 Suspension Method: In the suspension method, the resin is dispersed in an aqueous medium, and the drug is added under continuous stirring. Unlike the batch method, this approach is often used for drugs with very short solubility windows or for drugs that may degrade in solution. This method favorable for formulations where in situ resinate formation is intended and pediatric oral liquids and mucosal sprays.

Methodology:

1. **Resin Suspension:** Resin suspended in deionized water and allowed swelling (30–60 min).
2. **Drug Addition:** Drug (dissolved or dispersed) added under continuous stirring.
3. **Reaction Phase:** Mild agitation maintained for 4–8 hours to allow exchange reaction.
4. **Separation and Drying:** Resinate is centrifuge or filter. Washed and dried as described in batch method.

Key Control Parameters: Stirring speed and dispersion stability, Drug solubility and diffusion rate, Resin particle size (smaller particles offer greater surface area).^{69,71}

3.2.5 Solvent Evaporation Technique: Ideal for drugs with low aqueous solubility or sensitive to hydrolysis, and in advanced solid dosage forms (e.g., fast-dissolving tablets). A less common but highly controlled method where the drug is first dissolved in a volatile organic solvent (e.g., ethanol or methanol), and the resin is suspended in this solution. After sufficient contact, the solvent is evaporated under reduced pressure or vacuum drying, leaving behind drug adsorbed onto the resin. This method enables

encapsulation of hydrophobic or neutral ionizable drugs. It can produce highly uniform resonates. Challenges is risk of drug degradation during solvent exposure and not preferred for scale-up due to solvent handling concerns.

Methodology:

1. *Drug Solution Preparation:* Drug dissolved the drug in a volatile organic solvent (e.g., ethanol, acetone).
2. *Resin Dispersion:* Resin added into to the drug solution under stirring.
3. *Adsorption Phase:* Allowed for sufficient contact time (30–120 min) to enable drug adsorption into resin matrix.
4. *Solvent Removal:* Solvent removed by rotary evaporation or tray drying under reduced pressure.
5. *Post-processing:* Pulverized, sieved, and stored under desiccated conditions.

Key Control Parameters: Solvent selection (must dissolve drug but not degrade resin), Vacuum and temperature control, Solvent residual limits (per ICH Q3C guidelines)^{70,71}

3.3 Mathematical Models Describing Drug Release

To understand and predict the kinetics and mechanisms of drug release from ion exchange resins, several well-established mathematical models are employed. These models aid in correlating experimental data with the release mechanism, enabling optimization and quality control of resin-based drug delivery systems.^{61,62,66}

Pseudo-First Order Kinetics: This model assumes that the rate of drug release is proportional to the concentration of unbound drug remaining on the resin.

$$\ln(Q_e - Q_t) = \ln Q_e - k_1 \cdot t \quad (\text{Eq. 1})$$

Where:

Q_e = amount of drug released at equilibrium (mg or %)

Q_t = amount of drug released at time t

k_1 = first-order release rate constant (min^{-1})

Interpretation: Linear plots of $\ln(Q_e - Q_t)$ vs. t suggest first-order behavior. Applicable when ion exchange is the rate-limiting step, particularly for weakly bound drugs in aqueous media.^{61,62}

Pseudo-Second Order Kinetics: A more precise model for ion exchange reactions, especially when chemisorption or ionic displacement governs the process.

$$t/Q_t = 1/(k_2 \cdot Q_e^2) + t/Q_e \quad (\text{Eq. 2})$$

Where:

Q_t = amount of drug released at time t

k_2 = pseudo-second order rate constant ($\text{g/mg} \cdot \text{min}$)

Interpretation: A plot of t/Q_t vs. t yields a straight line. Often provides the best fit for resinate systems where interfacial exchange and ion competition are dominant factors.^{62,66}

Higuchi Model (Diffusion-Controlled Release): This model explains drug release as a diffusion process through a porous matrix (e.g., polymer-coated resinate particles or hydrophilic matrices).

$$Q_t = k_H \cdot \sqrt{t} \quad (\text{Eq. 3})$$

Where:

Q_t = cumulative amount of drug released at time t

k_H = Higuchi dissolution constant

Interpretation: A linear relationship between Q_t and $\sqrt{t}$ indicates a diffusion-controlled mechanism. This model is especially relevant when the resin is embedded in a hydrophilic polymer gel or compressed tablet.⁶⁹

Korsmeyer–Peppas Model (Mechanism Determination): Used when the release mechanism is not clearly defined or involves multiple concurrent processes such as diffusion, erosion, and ion exchange.

$$M_t/M_\infty = k \cdot t^n \quad (\text{Eq. 4})$$

Where:

M_t/M_∞ = fraction of drug released at time t

k = kinetic constant

n = release exponent indicative of mechanism

Interpretation of exponent n (for slab-shaped systems):

$n \leq 0.45$: Fickian diffusion

$0.45 < n < 0.89$: Anomalous (non-Fickian) transport

$n = 0.89$: Case II (relaxation-controlled) transport

$n > 0.89$: Super Case II (erosion/swelling dominated)

Application: This model is extensively used for polymer-coated resinate microparticles, osmotic tablets, and buccal patches.

Zero-Order Kinetics: Describes a release system where the drug is released at a constant rate, independent of concentration.

$$Q_t = Q_0 + k_0 \cdot t \quad (\text{Eq. 5})$$

Where:

Q_0 = initial amount of drug

k_0 = zero-order rate constant

Q_t = cumulative drug release at time t

Interpretation: Ideal for controlled-release formulations where steady plasma levels are desired. Achievable through coated resinates, membrane-enclosed beads, or matrix-resinate hybrids.

Weibull Model (Empirical Fit): An empirical model useful when drug release does not follow standard kinetics precisely.

$$F(t) = 1 - \exp(-(t - T_0)/\alpha^\beta) \quad (\text{Eq. 6})$$

Where:

$F(t)$ = fraction of drug released at time t

T_0 = lag time

α = scale parameter (time constant)

β = shape parameter (release curve profile)

Interpretation:

- $\beta < 1$: parabolic release (decelerating)
- $\beta = 1$: exponential release (first-order)
- $\beta > 1$: sigmoidal release (complex kinetics)

61,62,66,69

4. Applications of Ion Exchange Resins in Drug Delivery

Ion exchange resins (IERs) have transitioned from being inert excipients to versatile functional components in modern pharmaceutical technology. Their ion-binding characteristics, physicochemical compatibility, biocompatibility, and FDA acceptance have made them indispensable in the design of novel drug delivery systems. Their applications span across oral, mucosal, topical, transdermal, and parenteral routes, often solving challenges related to taste masking, drug stability, bioavailability, controlled release, and targeted delivery.⁷³⁻⁷⁵

4.1 Taste Masking of Bitter Drugs: Taste masking remains a primary pharmaceutical application of ion exchange resins, especially for drugs with high patient aversion due to bitterness or metallic aftertaste.

Mechanism of Taste Masking: Drugs bind to the oppositely charged functional groups on the resin surface (e.g., cationic drugs to sulfonic acid groups on cation exchange resins). In the neutral pH of saliva (~6.8), the ion exchange reaction does not proceed significantly, preventing drug release and thus blocking interaction with taste buds. Once swallowed, the acidic pH of the stomach (~1.2) or the ionic environment of the intestines facilitates rapid drug dissociation and absorption.^{73,74}

Common Drugs: Dextromethorphan, ranitidine, chlorpheniramine, ciprofloxacin, cetirizine, azithromycin

Formulation Examples: Syrups: Drug-resin complexes suspended in flavored vehicles (e.g., dextromethorphan polistirex), ODTs and Chewable Tablets: Incorporate resinate for palatability, Mouth-dissolving films and strips: Embedding drug-resin in polymeric matrices

Merits are: No need for sweeteners or bitterness suppressants, Suitable for heat-sensitive drugs due to mild processing conditions, Cost-effective and scalable.^{73,75}

4.2 Sustained and Controlled Release Formulations: IERs are instrumental in developing once-daily or extended-release formulations by modulating the rate of drug release based on ion exchange kinetics and polymer barrier control.

Mechanism: Drugs ionically bound to the resin are slowly exchanged with physiological counter-ions (e.g., Na^+ , Cl^-) present in GI fluids. The rate of exchange and subsequent release can be tailored by:

- Selecting appropriate resin crosslinking levels (affecting swelling and porosity)

- Applying rate-controlling coatings (e.g., ethylcellulose)
- Modulating particle size and drug-resin ratio.^{76,77}

Commercial Examples: **Tussionex®:** Hydrocodone polistirex with chlorpheniramine polistirex (12-hour release), **Repetabs®:** Diclofenac resinate with enteric and sustained-release coatings, **Diltia XT®:** Diltiazem bound to sulfonated polystyrene resin.

Technological Integrations: Coated Multiparticulates: Resinates coated with aqueous or organic polymers, Matrix Tablets: Embedded resinates in hydrophilic matrices for dual release, Osmotic Delivery: Resinates used in the drug core for ion-activated pumps.^{76,78}

4.3 Stabilization of Labile Drugs: Ion exchange resins offer protection to drugs vulnerable to degradation by acid, light, oxidation, or hydrolysis by forming ionic complexes that shield functional groups from the external environment.

Stabilization Mechanisms: Hydrophobic Microenvironments: Resins can hinder water penetration, Steric Hindrance: Ion pairing reduces accessibility to degradative agents, pH Buffering: Localized pH environment can be stabilized by resin type.^{79,80}

Evidence: Erythromycin-resinate: Stabilized against acid hydrolysis, Vitamins (e.g., B12): Prevents photodegradation, Nucleosides and cardiac glycosides: Improved shelf life.

Formulation Benefit: Enhances product robustness in tropical climates and long-term storage, Reduces dependence on chemical stabilizers and preservatives.

4.4 Mucoadhesive and Site-Specific Delivery: Ion exchange resins have been incorporated into delivery platforms that target specific mucosal sites, leveraging adhesiveness, ionic interaction, and swelling behavior for prolonged local drug residence.

Applications: Buccal tablets and films: Resinates (e.g., diclofenac, metronidazole) combined with mucoadhesive polymers like chitosan or Carbopol. Rectal and vaginal inserts: For antifungal or anti-inflammatory therapies. Colon-targeted systems: Exploit specific ionic triggers or enzymatic degradation

Advantages: Avoids first-pass metabolism. Allows lower dosages with site-specific action. Enhances therapeutic efficacy in local infections or inflammatory disorders.^{81,82}

4.5 Transdermal and Topical Drug Delivery: IERs can function as reservoir matrices or modulators in transdermal patches and topical gels, ensuring steady-state diffusion and ion-triggered release through the skin.

Mechanism: Ion-exchange-mediated release: Skin ions (Na^+ , Cl^-) facilitate drug displacement from resin.

Iontophoresis enhancement: Charged resins mobilized via electric current to improve penetration

Examples: Nicotine–resinate patches: Controlled delivery for smoking cessation. Topical clindamycin: Complexed with weak anion resins for controlled acne treatment. Lidocaine gels: Formulated with weak cationic resins for sustained dermal anesthesia.

Benefits: Minimizes systemic exposure and adverse effects. Enables once-daily or overnight application. Enhances stability in topical bases.^{83,84}

4.6 Targeted Gastrointestinal Drug Delivery: IERs serve as intelligent carriers for pH-dependent or enzyme-responsive release, enabling localization of drug action in specific segments of the gastrointestinal tract.

Approaches: Enteric-coated resinate pellets: Release drug in the intestine (e.g., budesonide–resinate for Crohn’s disease). Colonic delivery systems: Resinates formulated with pH-sensitive polymers (e.g., Eudragit® S100) that degrade in the colon. Floating tablets: Low-density resinate matrices prolong gastric residence for drugs like amoxicillin.

Benefits: Maximizes local bioavailability. Useful in treating site-specific infections, ulcers, or inflammation. Minimizes systemic exposure and related toxicity.^{85,86}

4.7 Ion-Activated and Osmotically Controlled Systems: IERs are essential in ion-activated and osmotic pump formulations, allowing for programmable, reproducible drug release profiles.

Ion-Activated Release: Drug release initiated by GI ions triggering displacement from resin

Example: Diphenhydramine–resinate in ion-responsive nasal sprays Osmotic Systems.

Formulation: Drug–resinate core enclosed by a semi-permeable membrane with laser-drilled orifices

Example: Diltiazem osmotic tablets (MUPS design) using sulfonated resins for controlled flux its minimizes effect of food or pH on release and provides high reproducibility and dose precision.^{87,88}

4.8 Pediatric and Geriatric Formulations: IERs are particularly useful in dose-flexible, easy-to-swallow formulations suited for children and elderly patients with swallowing difficulties or altered metabolism.

Formulations: Liquid suspensions: Stable resinate dispersions in flavored vehicles. Mini-tablets: Crush-resistant, taste-masked units. Sprinkle capsules: Resinates incorporated into beads for capsule filling

Examples: Chlorpheniramine resinate syrup, Sodium valproate resinates (for seizure control in pediatrics), Cefixime–resinate ODTs for age-specific respiratory infections.

Clinical Relevance: Improved compliance and therapeutic adherence. Minimizes risk of underdosing or overdosing in non-standard regimens.^{89,90}

4.9 Complex and Programmable Release Platforms: Recent innovations have integrated IERs into multi-mechanistic platforms involving layered dosage forms, coated beads, and chronotherapeutic systems.

Applications: Chronomodulated tablets: Resinates used to create a time-delayed pulse (e.g., prednisone–resinate for morning arthritis). Biphasic release systems: Immediate-release layer plus coated resinate core. Triple-layer tablets: Combine free drug, resin-complexed fraction, and polymer coating for phased delivery.

Technologies Involved: Fluidized bed coating, Hot melt extrusion of resinates, Ion–resin microparticles embedded in 3D-printed matrices.

Advantages: Personalization of therapy, Precise control over lag time, onset, and duration of release.^{91,92}

5. Factors Affecting Ion Exchange Behavior and Drug Release Performance

Ion exchange resins (IERs) are versatile pharmaceutical excipients that function through reversible ionic interactions between the active pharmaceutical ingredient (API) and the charged functional groups on the resin backbone. The drug loading efficiency, stability of the drug–resin complex (resinate), and release kinetics from IERs are modulated by a variety of intrinsic and extrinsic factors. Understanding and controlling these parameters is essential to ensure consistent therapeutic performance and formulation robustness.⁷³⁻⁷⁵

5.1 Nature and Strength of the Ion Exchange Resin

Functional Group Chemistry and Ion Exchange Capacity: The ion exchange capacity (IEC), usually expressed in milliequivalents per gram (meq/g), defines the total number of ionic sites available for binding. Strong cation exchange resins (e.g., sulfonated polystyrene) have IECs in the range of 4.0–5.5 meq/g. Strong anion exchange resins (e.g., quaternary ammonium) typically possess 3.0–4.5 meq/g.

Strong acid or base resins retain their ionic character over a wide pH range (pH 1–12), whereas weak acid/base resins exhibit pH-dependent ionization: Weak acid resins (e.g., carboxylic acid groups) lose ionization below pH 4. Weak base resins (e.g., tertiary amines) become non-ionized at pH > 9.

Backbone Polymer and Degree of Crosslinking: Most IERs are synthesized from styrene–divinylbenzene (DVB) copolymers. DVB content (typically 2–16%) controls crosslinking density: Low crosslinking (2–5%) results in increased swelling, higher permeability, and faster drug diffusion. High crosslinking (10–16%) provides structural rigidity and mechanical strength but limits resin hydration and exchange kinetics. In cellulose-based IERs, swelling is influenced by the

degree of substitution (DS) and the presence of hydrophilic hydroxyl groups.

Particle Size, Porosity, and Surface Area: Micronized resins ($\leq 100 \mu\text{m}$) provide greater contact surface and shorter diffusion paths, accelerating both drug loading and release. Macroporous resins with controlled pore diameter ($\sim 100\text{--}500 \text{ \AA}$) facilitate the exchange of larger drug molecules and reduce diffusional resistance. The BET surface area correlates with resin reactivity and is typically higher in gel-type resins compared to matrix-bound or coated ones.⁷³⁻⁷⁶

5.2 Drug Physicochemical Properties

Ionic Nature, pKa, and Charge Density: Ion exchange is feasible only for ionizable drugs, i.e., those that exist in a charged state under formulation or physiological conditions. pKa governs the degree of ionization. Optimal binding occurs when: Weakly basic drugs (e.g., diphenhydramine, pKa ~ 8.8) are complexed with CERs at acidic pH to ensure protonation (positively charged). Weakly acidic drugs (e.g., ibuprofen, pKa ~ 4.5) are complexed with AERs at basic pH to ensure deprotonation (negatively charged). Multivalent drugs or those with localized high charge density exhibit stronger binding due to enhanced electrostatic interaction.

Molecular Size and Steric Hindrance: High molecular weight drugs ($>500 \text{ Da}$) may not effectively diffuse into highly crosslinked or microporous resins. Steric hindrance, especially in bulky molecules, impedes access to internal exchange sites, reducing overall loading.

Hydrophilicity and Partition Coefficients: Hydrophilic drugs (low LogP) are more compatible with aqueous resin environments and exhibit higher exchange efficiency. Lipophilic drugs may require formulation with co-solvents or surfactants (e.g., polysorbates, polyethylene glycols) to facilitate partitioning into resin microenvironments.⁷⁷⁻⁷⁹

5.2 Environmental Parameters: pH, Ionic Strength, and Competing Ions

pH-Dependent Exchange Dynamics: Ion exchange is fundamentally pH-sensitive: For CERs: Drug release is favored at neutral to alkaline pH, where H^+ or metal cations (Na^+ , K^+) displace the drug. For AERs: Release is promoted in acidic pH, where Cl^- or other anions displace the bound drug. The buffering capacity of gastrointestinal fluids (e.g., pH 1.2 in the stomach, pH 6.8–7.4 in the intestine) is key to modulating release site and kinetics.

Ionic Strength and Competitive Displacement: In vitro, phosphate buffers or saline solutions simulate physiological ionic strength ($\sim 0.15 \text{ M NaCl}$). Higher ionic strength enhances exchange by increasing the concentration of counterions capable of displacing the drug. Selectivity sequence (Hofmeister series)

applies—resins preferentially bind certain ions (e.g., $\text{Ca}^{2+} > \text{Na}^+ > \text{H}^+$).⁸⁰⁻⁸²

5.4 Drug-to-Resin Ratio (D:R): Drug-to-resin molar or weight ratio influences: Binding capacity and complexation efficiency and drug release rate and loading uniformity. Optimal ratios are formulation-specific, typically in the range of 1:1 to 1:3 w/w for taste-masked or controlled-release products. Excess resin ensures full complexation but adds excipient bulk; insufficient resin leads to incomplete drug binding and release variability.⁸³

5.5 Temperature and Agitation Conditions: Temperature affects both: Resin swelling ($\uparrow$ temperature = $\uparrow$ hydration and pore expansion) and drug diffusion and resin–drug interaction kinetics (as per Arrhenius behavior). Agitation (e.g., magnetic stirring, shaking incubator) reduces stagnant diffusion layers and promotes dynamic equilibrium. Common loading conditions range between 25–40°C and 300–500 rpm for 2–6 hours depending on system design.⁸³⁻⁸⁴

5.6 Influence of Formulation Design and Processing Variables

Polymeric Coatings and Matrix Systems: Encapsulation in ethylcellulose, Eudragit® RS/RL, or HPMC modifies drug diffusion profiles:

- Eudragit RS: pH-independent slow release
- Eudragit L/S: pH-dependent enteric release
- HPMC: swellable hydrophilic matrix

Dual-coated resins (core–shell) provide bimodal release, combining immediate and sustained release phases.

Granulation and Drying: Wet granulation using binders like PVP, xanthan gum, or starch may affect resin swelling and compressibility. Fluidized bed coating preserves spherical geometry and allows multilayered drug–resin formulations. Drying methods (tray drying, spray drying, lyophilization) impact particle morphology, porosity, and moisture content.⁸⁵⁻⁸⁶

5.7 In Vivo Factors: GI Environment and Biological Interactions: Physiological counterions (Na^+ , Cl^- , K^+ , Ca^{2+} , HCO_3^-) facilitate drug displacement from resinate complexes. Variability in GI transit time and motility affects residence time and site-specific drug release. Interaction with bile salts, mucin, and digestive enzymes may alter resin surface characteristics or impact drug solubility. Food effect: co-administration with meals can change gastric pH and delay gastric emptying, potentially altering release patterns.⁸⁷⁻⁸⁸

5.8 Stability and Storage Parameters: Resinates are sensitive to humidity due to the hygroscopic nature of

both the resin and API. Exposure to light or elevated temperatures may result in: Degradation of heat-labile drugs and oxidation or desulfonation of resin functional groups. Controlled packaging (e.g., aluminum blisters, HDPE bottles with desiccants) ensures stability. ICH guidelines (e.g., Q1A(R2)) should be followed for accelerated and real-time stability studies on resin-based formulations.⁸⁹⁻⁹⁰

Table 3: Factors Influencing Ion Exchange Behavior and Drug Release from Ion Exchange Resins

Category	Specific Factor	Details	Effect on Drug Loading/Release
Resin Properties	Type of Functional Group	Strong (e.g., $-\text{SO}_3^-$, $-\text{NR}_4^+$) vs. Weak (e.g., $-\text{COOH}$, $-\text{NR}_3$)	Determines pH-responsiveness and binding stability ⁷³⁻⁷⁶
	Ion Exchange Capacity (IEC)	Typically 3–5.5 meq/g depending on resin type	Higher IEC enables greater drug binding ⁷³⁻⁷⁶
	Crosslinking Density	Low (2–5%) → more swelling; High (10–16%) → rigid structure	Influences hydration, diffusion, and mechanical stability ⁷³⁻⁷⁶
	Particle Size	Fine particles ($\leq 100 \mu\text{m}$) provide larger surface area	Enhances drug–resin interaction and release rate ⁷³⁻⁷⁶
	Porosity and Surface Area	Gel-type vs. macroporous resins with BET area variation	Affects molecular diffusion and accessibility to exchange sites ⁷³⁻⁷⁶

Category	Specific Factor	Details	Effect on Drug Loading/Release
Drug Properties	Ionization Constant (pKa)	Determines ionization state at a given pH	Critical for interaction with oppositely charged resin ⁷⁷⁻⁷⁹
	Charge and Valency	Monovalent, divalent, or multivalent drugs	Multivalent drugs show stronger, often slower exchange ⁷⁷⁻⁷⁹
	Molecular Size	High molecular weight or bulky drugs may be restricted	Affects resin site accessibility and loading efficiency ⁷⁷⁻⁷⁹
	Lipophilicity (LogP)	$\text{LogP} < 1$: hydrophilic; $\text{LogP} > 2$: lipophilic	Impacts resin compatibility and dispersion behavior ⁷⁷⁻⁷⁹
Environmental Conditions	pH of Medium	Influences ionization of both resin and drug	Drives complexation (loading) or release (displacement) ⁸⁰⁻⁸²
	Ionic Strength / Competing Ions	Presence of Na^+ , K^+ , Cl^- , HCO_3^-	Enhances or disrupts ion exchange via competitive displacement ⁸⁰⁻⁸²
	Temperature	Elevated temperatures increase resin swelling and diffusion	Accelerates binding and release kinetics ⁸⁰⁻⁸²

Category	Specific Factor	Details	Effect on Drug Loading/Release
	Agitation / Mixing	Controlled stirring enhances contact	Promotes equilibrium between free and bound drug ⁸⁰⁻⁸²
Formulation Parameters	Drug-to-Resin Ratio	Optimal ratio: 1:1 to 1:3 (w/w)	Affects loading capacity, release uniformity, and bulk ⁸³
	Coating or Matrix System	E.g., Eudragit®, HPMC, EC coatings	Enables pH-triggered, extended, or pulsatile release ⁸⁵⁻⁸⁶
	Granulation and Drying Method	Fluid bed, spray drying, lyophilization	Influences porosity, particle morphology, and moisture content ⁸⁵⁻⁸⁶
Biological Factors	Gastrointestinal pH & Transit	pH variation from stomach (1.2) to intestine (6.8–7.4); GI motility	Governs site and rate of drug release in vivo ⁸⁷⁻⁸⁸
	Food and Fluids	Influence on pH, drug solubility, and residence time	May delay or enhance ion exchange and drug availability ⁸⁷⁻⁸⁸
Stability Considerations	Storage Conditions	Temperature, humidity, and light exposure	Affects long-term integrity of drug–resin complex and functional stability ⁸⁹⁻⁹⁰

6. Characterization and Evaluation of Ion Exchange Resin-Based Formulations

6.1 Physicochemical Characterization of Ion Exchange Resins: A comprehensive understanding of the physicochemical properties of ion exchange resins is vital to predict and control drug-resin interactions, ensure batch-to-batch consistency, and optimize formulation design.^{73,74} The following parameters are central to the characterization process:

6.1.1 Particle Size and Morphology: Particle size affects the specific surface area, drug accessibility to exchange sites, resin packing behavior, and sedimentation in suspensions.^{75,76} Smaller particles offer increased surface area but may pose challenges in flow properties and processing.

Techniques and Considerations:

Laser Diffraction (LD): Measures particle size distribution in dry or wet states. Useful for bulk batches. Reports D10, D50, and D90 values.

Dynamic Light Scattering (DLS): Suitable for nanometer-scale resins or colloidal dispersions. Particularly useful for submicron or nanosized ion exchange resin particles used in advanced delivery systems.

Scanning Electron Microscopy (SEM): Reveals detailed surface topology—smooth (gel-type) vs. porous (macroporous). Can highlight surface cracks, roughness, or embedded drug crystals.

Optical Microscopy: Provides rapid, qualitative assessment of shape (spherical, irregular), surface roughness, and agglomeration.

Pharmaceutical Implication: Uniform particle size ensures consistent flow during tablet compression or capsule filling. Irregular or fine particles may affect sedimentation rate and redispersibility in suspensions.⁷⁵

6.1.2 Surface Area and Porosity: These factors directly affect the accessibility of the functional groups within the resin matrix, impacting drug loading kinetics and diffusion during release.

Techniques:

Brunauer–Emmett–Teller (BET) Analysis: Determines specific surface area (m²/g) using nitrogen adsorption–desorption isotherms. Pharmaceutical resins typically exhibit surface areas ranging from 5 to 80 m²/g depending on porosity.

Mercury Intrusion Porosimetry: Provides information on total pore volume and pore size distribution (micro-, meso-, and macropores).

Gas Adsorption/Desorption Studies: Offer insights into pore interconnectivity and tortuosity.

Implication: Macroporous resins (e.g., ≥ 50 nm pores) allow easier diffusion of large or hydrophobic drug molecules. Gel-type resins, with limited porosity, may restrict binding of larger drugs but ensure tighter interaction with small ionic molecules.⁷⁷

6.1.3 Ion Exchange Capacity (IEC): IEC is the fundamental measure of how many active ion-exchange sites are available per unit mass of resin. It determines the theoretical drug loading capacity.

Determination Methods:

Back Titration Method: Resin is saturated with a known excess of ionic solution (e.g., HCl or NaOH), washed, and the excess titrated with a standard solution. IEC (meq/g) is calculated using:

$$\text{IEC (meq/g)} = [C \times (V_{\text{blank}} - V_{\text{sample}})] / m$$

(Eq. 7)

where:

C = Concentration of titrant (mol/L or N)

V_{blank} = Volume of titrant required for blank (mL or L)

V_{sample} = Volume of titrant required for sample (mL or L)

m = Mass of dry resin taken (g)

Ion Chromatography (IC): Quantifies displaced counterions after saturation with a known ion source.

Atomic Absorption Spectroscopy (AAS): Measures released metal ions after exchange with known salts in the typical ranges for strong acid cation exchangers (e.g., sulfonic acid): 4.0–5.5 meq/g, weak acid cation exchangers (e.g., carboxylic): 3.0–4.0 meq/g and anion exchangers (quaternary ammonium): 3.0–4.8 meq/g.

High IEC resins may cause burst release if drug release is not modulated using matrix coatings or layered delivery systems. Conversely, low IEC resins may underperform for high-dose drugs.⁷⁸

6.1.4 Swelling Behavior and Moisture Content: Swelling governs the expansion of the resin network and accessibility of internal functional groups, influencing drug diffusion and ion exchange kinetics.

$$\text{SR (\%)} = [(W_{\text{swollen}} - W_{\text{dry}}) / W_{\text{dry}}] \times 100 \quad (\text{Eq. 8})$$

Where:

W_{swollen} = weight of the resin in swollen state

W_{dry} = weight of the resin in dry state

Procedure: Dry resin is weighed, then immersed in deionized water or buffer (e.g., pH 1.2, 4.5, 6.8), and allowed to swell at room or physiological temperature. Excess liquid is removed, and weight measured.

Factors Influencing Swelling: pH of medium, Ionic strength, Crosslinking density (Highly crosslinked resins swell less), Resin type (Gel-type resins swell more than macroporous ones).

Moisture Content: Karl Fischer Titration is accurate for low moisture levels (0.01% w/w precision). Used for batch control. Thermogravimetric Analysis (TGA) measures weight loss upon heating to 100–120 °C, corresponding to water content.

Implication: High moisture content may indicate poor storage or high hygroscopicity, affecting stability. Excessive swelling may hinder compressibility or

cause disintegration of solid dosage forms during storage.⁷⁹

6.2 Drug-Resin Complex (Resinate)

Characterization: The formation of a stable drug-resin complex, often referred to as a resinate, is critical to the functionality of ion exchange resin-based drug delivery systems. The characterization of these complexes ensures proper drug incorporation, stability, and performance across various formulation platforms. A combination of analytical, spectroscopic, thermal, and structural techniques is used to confirm and understand the nature of the drug-resin interaction.⁸⁰

6.2.1 Confirmation of Complex Formation: Before evaluating performance, it is essential to confirm that the drug has successfully bound to the resin matrix. This is typically accomplished through:

Differential Loading Technique: Comparison of drug content before and after resin exposure using validated quantitative methods (e.g., UV-Vis spectroscopy, HPLC).

Supernatant Analysis: After the loading process, the remaining free drug in the supernatant is quantified. The absence (or significant reduction) of drug confirms binding.

Conductometric or pH Monitoring: Ion exchange is often accompanied by a change in ionic concentration or pH due to the release of counter-ions. This shift can be monitored to confirm exchange.⁸⁰

6.2.2 Spectroscopic Characterization: Spectroscopic methods help identify potential molecular-level interactions and confirm changes in functional group environments due to drug binding.

Fourier-Transform Infrared Spectroscopy (FTIR): Detects characteristic shifts in vibrational peaks (e.g., –OH, –NH, –COO[–]) that indicate hydrogen bonding, electrostatic interaction, or chemical modification. Overlapping or diminished drug peaks confirm complexation.

Raman Spectroscopy: Complements FTIR in analyzing vibrational modes, especially for molecules with symmetric bonds.

UV-Visible Spectroscopy: Useful for assessing surface-bound drug content and studying drug leaching profiles.⁸⁰

6.2.3 Thermal Analysis: Thermal characterization provides insight into changes in thermal behavior of the drug upon complexation, which may indicate molecular-level encapsulation or altered crystallinity.

Differential Scanning Calorimetry (DSC): Pure drugs typically exhibit sharp endothermic melting peaks. The disappearance or broadening of these peaks in resinates suggests amorphization or drug encapsulation within the resin matrix.

Thermogravimetric Analysis (TGA): Evaluates the thermal stability and degradation profiles of resinates

versus pure drug or resin alone. Provides moisture content as well.

Hot-Stage Microscopy: Visualizes phase transitions (melting, decomposition) under a polarized light microscope in real time.⁸⁰

6.2.4 Crystallinity and Structural Properties: Drug crystallinity can significantly influence solubility and bioavailability. Many drug-resin interactions lead to reduced crystallinity or complete amorphization.

Powder X-ray Diffraction (PXRD): Sharp peaks in pure drug diffractograms typically disappear or flatten in resins, confirming reduced crystallinity or transformation to amorphous form.

Solid-State NMR (ssNMR): Offers atomic-level resolution for structural elucidation of resin-drug interactions, especially for amorphous formulations.⁸⁰

6.2.5 Surface Morphology and Topography: Changes in surface features provide visual confirmation of drug loading and distribution over the resin surface.

Scanning Electron Microscopy (SEM): Used to compare surface texture before and after drug loading. Drug crystals may appear as surface deposits if not fully encapsulated.

Atomic Force Microscopy (AFM): Provides nanometer-resolution surface topography and roughness measurements. Useful for assessing the homogeneity of coating or layering.⁸⁰

6.2.6 Elemental and Chemical Mapping: These techniques help verify drug incorporation at the elemental level and map its distribution.

Energy Dispersive X-ray Spectroscopy (EDS/EDX): Coupled with SEM, it helps detect elemental signatures of drugs (e.g., Cl⁻, Na⁺, S, P) indicating presence and distribution within the resin matrix.

X-ray Photoelectron Spectroscopy (XPS): Detects surface-level chemical changes and provides insights into binding energies and oxidation states of the drug or functional groups post-complexation.⁸⁰

6.2.7 Drug Content and Loading Efficiency: Accurate quantification of drug loading is critical for dose uniformity and therapeutic consistency.

LE (%) = (Amount of drug loaded / Initial amount of drug used) × 100 (Eq. 9)

DC (%) = (Amount of drug loaded / Total weight of resin) × 100 (Eq. 10)

Where:

Amount of drug loaded =
drug successfully bound to the resin
Initial amount of drug used
= drug taken initially for loading
Total weight of resin =
drug-resin complex weight

Analytical Methods: UV-Vis spectrophotometry, HPLC, and LC-MS/MS are commonly used after drug extraction from resin using appropriate solvents or ion-exchange media.⁸⁰

6.2.8 In Vitro Release Characterization: Although detailed release mechanisms are discussed in Section 3.2, in vitro studies remain a vital component of resin characterization.

Dissolution Testing (USP Apparatus I/II/IV): Evaluates pH-dependent release, ion-exchange-mediated liberation, and potential burst effects.

Dialysis Membrane Studies: Separates free drug from unbound or resin-bound forms to study exchange dynamics under controlled ionic conditions.

Sink and Non-sink Conditions: Help simulate physiological versus supersaturated environments, especially for modified-release systems.⁸¹

6.3 In Vitro and In Vivo Evaluation of Ion Exchange Resin-Based Formulations: The successful development of ion exchange resin (IER)-based drug delivery systems hinges on thorough evaluation under both in vitro and in vivo conditions. These evaluations are crucial to demonstrate the safety, efficacy, and performance of the formulation across various physiological environments. This section outlines the strategies and analytical tools used to assess drug release behavior, pharmacokinetics, and therapeutic equivalence of IER-based formulations.

6.3.1 In Vitro Evaluation:

A. Dissolution Testing: Dissolution studies are essential to assess the drug release characteristics of resins. These tests simulate the physiological conditions of the gastrointestinal tract and help predict the release kinetics of ion-exchange systems.⁸¹

Standard Apparatus: USP Apparatus I (Basket) and Apparatus II (Paddle) are commonly used. USP Apparatus IV (Flow-Through Cell) is especially suitable for modified-release formulations.⁸¹

Medium Selection: pH 1.2 (simulated gastric fluid), pH 4.5 (acetate buffer), and pH 6.8 (simulated intestinal fluid) to mimic GI transit. Use of counter-ion rich media (e.g., NaCl, KCl solutions) facilitates ion-exchange-based release.⁸¹

Evaluation Parameters: Cumulative % drug released over time, T₅₀ (time for 50% release), Dissolution efficiency (DE%)⁸¹

B. Kinetic Modeling of Release Profiles: Modeling helps elucidate the mechanism of drug release and the influence of resin properties on release rate. Zero-order, first-order, Higuchi, Hixson-Crowell, Korsmeyer-Peppas, and Weibull models are typically applied.⁸²

Mechanistic insights: Diffusion-controlled: Higuchi, Swelling or erosion-controlled: Korsmeyer-Peppas (n > 0.5), Ion-exchange driven: often fits modified first-order or Weibull models.⁸²

C. Stability Testing: Drug-resin complexes are subjected to accelerated (ICH guidelines) and long-term stability studies to ensure retention of drug content, release profile, and physical integrity.⁸²

Conditions: 40 °C/75% RH for 6 months (accelerated), 25 °C/60% RH (long-term)

Parameters: Drug content, in vitro release, appearance, moisture uptake

D. Disintegration and Swelling Studies (for ODTs, capsules): Evaluate how rapidly resin-based tablets disintegrate and swell in aqueous media. Swelling index correlates with release performance in mucoadhesive or gastric-retentive systems.⁸²

E. Mucoadhesion or Ion Exchange Retention (if applicable): For buccal, nasal, or gastroretentive systems: Mucoadhesive strength, residence time, and ion-exchange persistence can be assessed using mucin-binding assays or ex vivo gut sac studies.⁸²

6.3.2 In Vivo Evaluation: In vivo testing is critical to establish the pharmacokinetic (PK), pharmacodynamic (PD), and safety profiles of resin-based drug delivery systems. These studies ensure translation of in vitro behavior to therapeutic performance.⁸³

A. Animal Pharmacokinetic Studies: Species Used: Rats, rabbits, and beagle dogs are commonly used for preclinical testing.⁸³

Parameters Evaluated: C_{max} (peak plasma concentration), T_{max} (time to reach C_{max}), AUC (area under the plasma concentration–time curve), Half-life (t_{1/2}), Bioavailability (%F).⁸³

Blood Sampling and Bioanalysis: HPLC, LC–MS/MS, or ELISA methods are validated for quantifying drug levels in plasma.⁸³

B. Pharmacodynamic (PD) Studies: Relevant in cases where therapeutic effect (e.g., antihistaminic, anti-inflammatory, or analgesic response) can be measured. Behavioral or biomarker assays are used to evaluate efficacy (e.g., % inhibition of induced edema or allergic response).⁸³

C. Gamma Scintigraphy and Imaging (for targeted delivery) Radio-labeling of resins helps in visualizing GI transit, site-specific release, or gastroretention using SPECT or PET imaging.⁸³

D. Toxicity and Biocompatibility Studies: Acute and sub-chronic toxicity evaluations in rodents, Local tolerance studies (oral mucosa, gastric epithelium), Hematology, histopathology, and organ function (ALT, AST, creatinine) assessment for safety profiling.⁸³

E. Comparative Bioequivalence Studies: Required for ANDA submissions involving IER-based formulations (e.g., taste-masked or modified-release generics).⁸³

Study Design: Crossover studies in healthy human volunteers (n ≥ 12–24), Regulatory compliance with FDA, EMA, or CDSCO guidelines, Acceptance Criteria: 90% CI of test/reference ratios for C_{max} and AUC within 80–125% range.⁸³

6.3.3 In Vitro–In Vivo Correlation (IVIVC): Development of a predictive correlation between in

vitro dissolution and in vivo absorption is highly valuable, especially for modified-release resinate systems. Level A correlation (point-to-point) is most desirable and accepted for regulatory biowaivers. IVIVC can reduce the need for repeated in vivo studies and aid in formulation optimization.⁸⁴

6.3.4 Special Considerations

Pediatric and Geriatric Populations: Taste-masking, ease of swallowing, and controlled release must be tailored to age-specific physiological needs.⁸⁴

Food Effects: Resinates can exhibit altered release with food-induced pH and ion concentration changes; fed/fasted studies may be warranted.⁸⁴

First-Pass Avoidance Strategies: Buccal or colonic delivery using IERs may help circumvent hepatic metabolism.⁸⁴

7. Regulatory and Quality Considerations for Ion Exchange Resin-Based Formulations:

The inclusion of ion exchange resins (IERs) in pharmaceutical formulations necessitates comprehensive regulatory oversight and quality control to ensure safety, efficacy, and compliance with global standards. Given their dual role as excipients and functional agents in drug delivery, IERs must satisfy excipient regulations as well as criteria for drug substance interaction, stability, and performance. This section outlines the key regulatory pathways, compendial standards, and quality assurance practices applicable to resin-based pharmaceutical systems.^{85,86}

7.1 Regulatory Classification and Approval Pathways

A. Regulatory Status of IERs: Ion exchange resins used in pharmaceuticals are typically classified as inactive ingredients (excipients) or functional excipients with taste-masking, controlled-release, or drug-binding properties.

FDA (U.S.): Resins such as polystyrene sulfonate and cholestyramine are listed in the FDA Inactive Ingredient Database (IID) and approved for various dosage forms. If used for novel purposes (e.g., sustained release), resins may be subject to review as novel excipients under FDA guidance.

EMA (Europe): IERs are regulated under the European Pharmacopoeia (Ph. Eur.) and ICH guidelines. Novel applications may require a risk-based assessment or a Drug Master File (DMF) for quality assurance.⁸⁷

CDSCO (India): Follows ICH-aligned practices; excipients must be justified with safety and functional data. Resin-based generics require comparative in vitro/in vivo studies.⁸⁸

B. Approval Pathways

New Drug Applications (NDAs): Required when resin functionality significantly modifies pharmacokinetics or introduces a new therapeutic indication.

Abbreviated New Drug Applications (ANDAs): Applicable when IERs are used in generics (e.g., taste-

masked cetirizine resinate), supported by bioequivalence data.

GRAS and DMF Submissions: Manufacturers may submit GRAS (Generally Recognized As Safe) or Type IV DMFs for proprietary resin formulations used in regulated drug products.⁸⁹

7.2 Compendial Standards and Monographs

Ion exchange resins included in official pharmacopeias must meet defined identity, purity, and performance specifications:

United States Pharmacopeia (USP): Monographs available for Cholestyramine Resin, Colestipol, Polystyrene Sulfonate, etc. Tests include resin capacity, loss on drying, particle size, swelling ratio, and residual monomers.

European Pharmacopoeia (Ph. Eur.): Includes resins under monographs such as *Colestyramine Resin, Light*. Requires compliance with specifications on microbial quality, heavy metals, and functional groups.

Japanese Pharmacopoeia (JP): Lists similar specifications for ion exchange polymers used in both therapeutic and excipient capacities.^{90,91}

7.3 Quality Assurance and GMP Compliance

Pharmaceutical-grade resins must be manufactured and handled in accordance with Good Manufacturing Practices (GMP) and subject to rigorous quality control.^{92,93}

Table 4: Quality Control Tests

Parameter	Purpose	Test Methods 93,94
Identity	Confirm polymeric structure and ion-exchange group	IR Spectroscopy, elemental analysis
Ion Exchange Capacity	Evaluate efficiency of ion exchange	Titrimetric methods (Na ⁺ /H ⁺ or Cl ⁻ /OH ⁻ exchange)
Swelling Index	Assess hydration and release potential	Gravimetric or volumetric methods
Particle Size Distribution	Ensure uniformity for reproducible drug loading	Laser diffraction, sieving
Residual Monomers	Confirm safety and compliance	GC, HPLC
Microbial Load	Ensure microbial quality standards	Total aerobic count, yeast/mold count
Heavy Metals	Control potential toxicity	AAS or ICP-MS

Parameter	Purpose	Test Methods 93,94
Stability	Evaluate long-term performance	ICH stability studies

8. Recent Advances and Emerging Trends in Ion Exchange Resin-Based Drug Delivery: Ion exchange resins (IERs), long recognized for their ability to bind ionic drug molecules and modulate release kinetics, are experiencing renewed attention as advanced drug delivery systems evolve. With increasing demand for precision therapeutics, patient-centric formulations, and improved bioavailability of poorly soluble or unstable drugs, recent innovations are repurposing IERs into novel delivery platforms. This section highlights key advances and emerging trends in the field, reflecting the intersection of polymer science, nanotechnology, and pharmaceutical engineering.⁹⁵

8.1 Smart and Stimuli-Responsive Resin Systems: One of the most significant trends in modern drug delivery is the development of stimuli-responsive ion exchange resins—formulations that release drugs in response to specific internal or external stimuli.

pH-sensitive IERs: These systems exploit changes in pH along the gastrointestinal (GI) tract or in pathological environments (e.g., tumor microenvironments) to trigger drug release. For example, weakly acidic cation exchange resins can retain basic drugs in the acidic stomach and release them in the neutral intestine.

Thermo-responsive IER composites: Incorporation of IERs into thermosensitive hydrogels or smart polymers (e.g., PNIPAM) enables temperature-triggered release, especially valuable in localized therapies or transdermal systems.

Redox-sensitive and enzyme-responsive systems: Emerging designs integrate redox-labile linkages or enzyme-cleavable moieties onto the resin backbone, facilitating site-specific release, especially in cancer or inflammatory tissues.^{96,98}

8.2 Ion Exchange Nanocomposites and Nanoformulations: Recent years have seen the miniaturization of IER-based systems into nano-scale platforms for targeted, controlled, or systemic delivery.

Resin Nanoparticles: Ultra-fine resin particles (<200 nm) enhance cellular uptake and surface interaction, ideal for mucosal or pulmonary delivery. Techniques such as high-pressure homogenization, spray drying, and nanoprecipitation are employed.

IER-Loaded Nanocarriers: Ion exchange mechanisms are being incorporated into:

Lipid nanoparticles (for ionic drugs with stability issues)

Polymeric micelles (where ionic binding enhances encapsulation)

Layered nanocomposites (e.g., resin-coated quantum dots or magnetic cores for theranostic applications)

Hybrid Nanogels: Incorporating IERs into crosslinked nanogels (e.g., polyacrylic or dextran-based) enhances drug loading, retention, and mucoadhesion, particularly for mucosal or ocular delivery.^{99,100}

8.3 Advanced Resin Engineering and Surface Modification: To improve biocompatibility, selectivity, and functional performance, recent work has focused on customizing the surface and structure of ion exchange resins.

Surface grafting and PEGylation: Improves dispersion, reduces immune recognition, and provides steric stabilization in biological media.

Molecular imprinting on resins: Enhances selective drug binding by engineering receptor-like cavities into the resin matrix, resulting in template-specific release.

Hierarchical pore structure optimization: New fabrication techniques allow for controlled macro-, meso-, and microporosity, improving ion diffusion, drug loading, and release control.^{96,101}

8.4 IERs in Multi-Unit and Multiparticulate Systems: The rise of multiparticulate drug delivery systems (MDDS), including microbeads, pellets, and mini-tablets, has aligned well with the use of ion exchange resins for, *Chronotherapeutics:* Tailoring drug release to circadian rhythms using coated resinate cores in pulsatile systems. *Pediatric and geriatric dosage forms:* Taste-masked, dispersible resins in oral sachets, reconstitutable suspensions, or orally disintegrating films. *Fixed-dose combinations (FDCs):* Use of resins to separate incompatible drugs within a single unit, enabling programmable release profiles.⁹⁹

8.5 Biomedical and Non-Oral Delivery Applications: IERs are being explored beyond traditional oral dosage forms: *Transdermal patches:* Ionic drugs complexed with resins are incorporated into adhesive patches for sustained dermal or systemic delivery. *Buccal and nasal systems:* Mucoadhesive IERs enable localized release with prolonged residence time and bypass of first-pass metabolism. *Implants and wound dressings:* IERs are embedded in biodegradable scaffolds for localized delivery of antimicrobials or anti-inflammatories. *Ophthalmic formulations:* Resin-based in situ gels offer controlled intraocular delivery of ionic drugs like timolol or dexamethasone.⁹⁹

8.6 IERs in Drug Detoxification and Biosorption: Beyond delivery, IERs are also employed in drug scavenging and detoxification platforms, including: *Overdose management:* Resins such as polystyrene sulfonate are under study for binding and neutralizing overdose of specific ionic drugs (e.g., digoxin, lithium). *Dialysis adjuncts:* Functionalized IERs are incorporated into extracorporeal systems to selectively

remove toxins or metabolites. *Oral biosorbents:* IERs are used to reduce systemic absorption of endotoxins or bile acids, with implications for metabolic, hepatic, and GI disorders.⁹⁵

8.7 Regulatory and Commercial Trends Supporting Innovation: Novel Excipient Qualification (FDA): Allows formal pre-submission review of innovative IERs used in advanced formulations. *Patient-centric design trends:* Drive the use of IERs for customized dosing, modular drug release, and taste-masking in pediatric and geriatric populations. *Biopharmaceutical Classification System (BCS) considerations:* IERs are increasingly used to enhance the solubility and bioavailability of BCS Class II/IV drugs via ionization-mediated mechanisms.⁹⁵

8.8 Ongoing Challenges and Future Outlook: Despite progress, several issues remain: Biocompatibility and biodegradability of synthetic resins, particularly for long-term or implantable use. Scale-up and reproducibility of nano- and composite systems incorporating IERs. Regulatory harmonization across regions for novel resin functionalities. Future developments are likely to be driven by interdisciplinary innovations, such as: AI-assisted resin selection and formulation design. Resin-protein conjugates for biologic stabilization. Bio-responsive IERs integrated with diagnostic sensors (theranostics)⁹⁵

9. Challenges, Limitations, and Future Perspectives in Ion Exchange Resin-Based Drug Delivery: Ion exchange resins (IERs) have shown significant potential as functional excipients and active delivery vehicles in pharmaceutical science.^{102,103} Their ability to form complexes with charged drugs, enable controlled release, and enhance patient compliance has resulted in widespread adoption across various dosage forms.¹⁰⁴ However, as with any enabling technology, the application of IERs is not without limitations.¹⁰⁵ A nuanced understanding of these challenges is crucial for optimizing existing systems and guiding future innovations. This section explores the multidimensional barriers associated with IER-based drug delivery, followed by emerging strategies and visionary perspectives for overcoming them.

9.1 Challenges in Formulation Development

9.1.1 Ionization Dependency and Limited Scope for Neutral Molecules: A foundational challenge lies in the dependence of ion exchange processes on the presence of ionizable functional groups in the drug molecule.¹⁰⁶ IERs interact only with cationic or anionic moieties under appropriate pH conditions. Consequently, neutral, non-ionizable, or weakly ionizing compounds ($pK_a < 3$ or > 11) are generally not amenable to resin complexation. This limits their applicability for a wide range of pharmacologically relevant APIs, particularly those with low aqueous

solubility and limited protonation under physiological conditions.¹⁰⁷

9.1.2 Predictability and Reproducibility of Drug-Resin Interactions: The kinetics and thermodynamics of drug-resin complex formation are influenced by several intertwined variables including drug pKa, resin crosslinking density, surface area, ionic capacity, and medium pH.¹⁰⁸ Variability in drug loading efficiency, binding strength, and desorption kinetics often complicates the formulation process.¹⁰⁹ Moreover, the optimization of parameters such as resin particle size, porosity, and moisture content is empirical and labor-intensive, necessitating extensive experimental work and multivariate design of experiments (DoE) to ensure reproducibility.

9.1.3 Controlled Release Versus Bioavailability Trade-Offs: While IERs are capable of modulating drug release over extended durations, over-complexation or excessively strong ionic bonding can lead to incomplete drug release or delayed onset of action,¹¹⁰ especially in low-ionic-strength physiological environments. This necessitates fine-tuning of the drug-to-resin ratio, resin functional group strength, and formulation matrix composition to balance therapeutic release profiles with pharmacokinetic objectives.¹¹¹

9.2 Manufacturing and Scale-Up Limitations

9.2.1 Particle Size and Flowability Constraints: IERs, especially strong polystyrene-based or macroreticular grades, exhibit irregular particle shapes and broad size distributions.¹¹² These morphological characteristics lead to suboptimal powder flow, poor die filling,^{112,113} and segregation during tableting or capsule filling. While micronization can improve homogeneity, it may also reduce ion exchange capacity due to decreased internal surface area.

9.2.2 Complexity in Producing Multiparticulate Systems: Advanced resin-based dosage forms—such as pellets, microspheres, nanocomposites, and bilayer tablets—often involve complex multistep processes, including fluidized bed coating, spray drying, or solvent evaporation.¹¹⁴ These processes are challenging to scale due to process sensitivity, agglomeration risks, equipment constraints, and yield losses.¹¹⁵

9.2.3 Functionalization and Customization Challenges: Tailoring IERs through chemical functionalization or surface modification is a promising strategy for enhancing selectivity, biocompatibility, and responsiveness.¹¹⁶ However, batch-to-batch reproducibility, cost of modification, and regulatory documentation of new excipient functionalities present barriers to industrial application. Customized resins often lack standardized monographs, requiring full toxicological and physicochemical characterization.¹¹⁷

9.3 Biocompatibility, Safety, and Toxicology Considerations

9.3.1 Non-Biodegradability and Accumulation Risks: Most pharmaceutical-grade synthetic IERs—such as styrene-divinylbenzene or acrylic copolymers—are non-degradable under physiological or environmental conditions. If not completely eliminated, residual resin particles can accumulate in the gut or renal system. This concern is heightened in chronic administration, pediatric or elderly populations, and in patients with gastrointestinal disorders.¹¹⁸

9.3.2 Leaching of Residual Monomers and Solvents: During resin synthesis, residual monomers (e.g., styrene, methacrylic acid) and initiators may persist in trace amounts. Unless properly removed by washing and purification, these low molecular weight impurities can be cytotoxic or carcinogenic. Rigorous control of residual solvents and extractables is essential to comply with ICH Q3C and USP <467> guidelines.¹¹⁹

9.3.3 Surface Reactivity and Immunogenicity: Modified resins bearing PEG chains, peptides, or targeting ligands may trigger complement activation or immune hypersensitivity, especially upon repeated exposure. Nanoparticulate resin formulations, while promising in drug targeting, require careful evaluation of size, charge, and zeta potential to avoid unanticipated immunological reactions or macrophage uptake.¹²⁰

9.4 Regulatory, Compliance, and IP Barriers

9.4.1 Regulatory Gaps for Novel Resin-Based Systems: While several IERs are recognized under pharmacopeial monographs, innovative formulations using novel crosslinkers, natural polymeric matrices, or functionalized surfaces may fall outside the scope of established excipient safety databases. Such systems often face additional scrutiny by regulatory bodies, requiring full excipient toxicology dossiers, long-term stability data, and biocompatibility testing under ICH, FDA, and EMA guidelines.¹²¹

9.4.2 Intellectual Property and Patentability: Patentability of resin-based systems can be hindered by prior art saturation, broad claims, and overlapping use cases. Patents covering resin composition, drug loading techniques, and therapeutic applications must be carefully crafted to establish novelty and utility. Furthermore, freedom-to-operate (FTO) assessments are essential to avoid infringement, particularly when using proprietary resins from commercial suppliers.¹²²

9.5 Environmental and Sustainability Challenges

9.5.1 Resin Waste Disposal and Ecotoxicology: Non-biodegradable synthetic resins contribute to solid pharmaceutical waste, especially in large-scale production settings. If improperly handled, discarded resins can become a source of microplastic pollution, adversely impacting aquatic ecosystems and

bioaccumulating in the food chain. Formulation developers are under increasing pressure to ensure eco-friendly disposal and lifecycle management.¹²³

9.5.2 Green Chemistry and Renewable Resin Sources: The current reliance on fossil-derived monomers and organic solvents in resin synthesis contradicts the principles of green chemistry. Emerging trends focus on developing sustainably sourced or biodegradable IERs from cellulose, lignin, chitosan, and alginate backbones. However, these innovations require significant R&D investment and validation to ensure comparable ion exchange capacity and mechanical stability.¹²⁴

9.6 Future Perspectives and Technological Directions: Despite the aforementioned limitations, IERs hold considerable promise as next-generation delivery systems. The following research avenues and innovations are poised to transform the field:

Development of Biodegradable and Natural Polymer Resins: Replacing polystyrene backbones with polysaccharides, silk fibroin, starch derivatives, or recombinant biopolymers may enable eco-friendly and biocompatible drug carriers.¹²⁵

Integration of Smart and Responsive Elements: pH-sensitive, redox-responsive, temperature-activated, or enzyme-triggered IERs are under exploration for on-demand or site-specific drug release, especially in inflammatory, tumor, or gastrointestinal microenvironments.¹²⁶

Machine Learning for Predictive Modeling: AI and ML algorithms are being leveraged to model resin-drug interaction energetics, release profiles, and resin matrix optimization, significantly accelerating formulation development.¹²⁷

3D Printing and Personalized Medicine: IERs embedded in printable matrices or hydrogel inks may allow patient-specific dosage tailoring, controlled polypharmacy, and rapid prototyping of personalized drug devices.¹²⁸

Combination Platforms with Biosensors and Implants: Resin-based systems may be integrated with biosensors for theranostic applications, releasing drugs in response to real-time biomarkers or physiological triggers.¹²⁹

Regulatory Harmonization and Novel Excipient Approval Pathways: Ongoing efforts to establish global harmonization of excipient evaluation, such as the IPEC initiative, may accelerate the path to market for advanced IER-based systems.¹³⁰

10. Conclusion: Ion exchange resins (IERs) have emerged as versatile, multifunctional excipients and delivery vehicles in modern pharmaceutical technology, playing pivotal roles that extend beyond simple drug carriers. Their unique physicochemical properties—including reversible ion-exchange capabilities, customizable polymeric backbones, and

structural stability across a wide pH range—make them highly adaptable for a broad array of dosage forms. From conventional oral tablets and suspensions to advanced systems such as colon-targeted capsules, bioadhesive gels, sustained-release microspheres, and nanocomposites, IERs have continually evolved in their application scope. Their ability to form stable drug–resin complexes (resinates) enables modification of pharmacokinetics, masking of unpleasant tastes, and enhancement of drug stability and bioavailability. The diverse classification of IERs—ranging from strong or weak cationic and anionic resins to ampholytic and natural polymer-based matrices—offers extensive opportunities for tailored formulation design. Recent innovations have further extended the utility of IERs into the realms of stimuli-responsive systems, multiparticulate drug delivery, and personalized medicine. Their integration into complex delivery strategies such as chronotherapeutic formulations, fixed-dose combinations, and site-specific targeting demonstrates the maturity and adaptability of IER platforms in addressing unmet clinical needs.

Despite their versatility, several formulation challenges persist. Ion exchange behavior is highly dependent on drug ionization potential, pH of the surrounding environment, and the ionic strength of physiological fluids. Moreover, certain practical limitations—including restricted applicability for non-ionizable compounds, incomplete drug release under low-ionic conditions, and difficulties in scaling multiparticulate resin systems—require careful formulation strategies. The balance between effective drug loading and controlled release remains a delicate aspect of IER utilization.

From a regulatory perspective, the incorporation of novel or modified IERs into pharmaceutical products introduces additional complexities. While several resins are pharmacopeia-listed and GRAS-recognized, newer synthetic or functionalized resins may necessitate rigorous toxicological evaluation, biocompatibility testing, and detailed excipient documentation. This is particularly relevant in global regulatory submissions, where harmonization efforts such as ICH and IPEC guidelines are vital for streamlining approval processes.

Equally significant are the biocompatibility and safety considerations, especially for long-term or pediatric formulations. Issues such as non-biodegradability, potential monomer leaching, and immune reactivity need to be addressed through the development of safer resin backbones and eco-conscious manufacturing practices. The drive toward sustainability is also catalyzing interest in biodegradable and renewable IERs derived from lignocellulosic and marine polysaccharides.

Looking ahead, the future of ion exchange resin technology is bright, underpinned by several transformative research directions. The integration of IERs into nanocarriers, hybrid hydrogels, implantable devices, and diagnostic biosensors opens avenues for site-specific, intelligent drug release. Concurrently, computational modeling, artificial intelligence, and machine learning are being applied to optimize resin-drug interactions and accelerate formulation development. The combination of IERs with cutting-edge manufacturing techniques, such as 3D printing and microfluidics, may further enable personalized drug therapies with unparalleled precision and adaptability.

In conclusion, ion exchange resins stand at the intersection of pharmaceutical functionality, chemical versatility, and clinical utility. Their role as excipients has expanded significantly, making them indispensable tools in the design of innovative, patient-centric, and regulatory-compliant drug delivery systems. By addressing current limitations through targeted research and collaborative standardization, IER-based formulations are poised to contribute meaningfully to the next generation of therapeutics in an era of precision and sustainability.

Conflict of Interest: The authors declare that they have no competing interests or financial conflicts regarding the publication of this manuscript.

Ethical Approval: Not applicable as this study does not involve human participants or animal subjects.

Funding Support: Self-funded. No external funding was received for this study.

Authors' Contributions: Dr. S.Gopinath, Dr. P.Selva kumar, Saravanan.S, Supervised the technical compilation, reviewed the mathematical kinetics models, and executed the critical intellectual formatting of final draft adjustments. All authors read and approved the final manuscript for publication.

References

- Loftsson T. Excipient pharmacokinetics and profiling. *Int J Pharm.* 2015;480(1-2):48-54.
- Awasthi R, Kulkarni GT, Pawar VK, Garg G. Ion exchange resins: An approach for the development of controlled release drug delivery systems. *Int J Pharm Sci.* 2011;3(2):7-15.
- Chattopadhyay P, Shekunov BY, Yim DS. Controlled release of diclofenac sodium using ion-exchange resins. *Drug Dev Ind Pharm.* 2001;27(5):447-454.
- Sharma G, Mehta S, Satija S, Garg T, Raina N, Singh B, et al. Ion exchange resin-based drug delivery systems: a review of design, formulation and applications. *Drug Dev Ind Pharm.* 2020;46(12):1939-1952.
- Liu Y, Tang W, Ji J, Yu L, Yu X. Bile acid sequestrants and their applications: a review. *Drug Des Devel Ther.* 2020;14:3363-3378.
- Sullivan JC, Fadrowski J, Neu AM. The use of sodium polystyrene sulfonate in hyperkalemia. *Clin Nephrol.* 2019;91(Suppl 1):75-80.
- Lindner D, Lippold BC. Drug release from ion-exchange resinate complexes. *Pharm Res.* 1995;12(12):1793-1797.
- Jain AK, Duvvuri LS, Kushwah V, Jain S. Advances in the pharmaceutical development of novel ion-exchange resins. *Asian J Pharm Sci.* 2021;16(5):623-640.
- Watanabe J, Likhitwitayawuid K, Takeuchi H, Yamamoto H, Kawashima Y. Effect of resin characteristics on drug loading and release behavior. *J Pharm Sci.* 2005;94(1):42-55.
- Patra S, Madhusudan P, Murthy PN, Swain S. Taste masking of etoricoxib by ion-exchange resin. *Pharm Dev Technol.* 2010;15(5):511-517.
- Rajesh A, Popat KM. Taste masking of ofloxacin by resin and interpenetrating polymer network beads. *J Pharm Anal.* 2017;7(4):244-251.
- Darwish I, Bond J, Bressler R, Boellner S, Childress A, Lopez FA, et al. Clinical pharmacokinetics of methylphenidate extended-release formulations: a comparison of an oral suspension and a chewable tablet. *Clin Pharmacokinet.* 2018;57(2):175-188.
- Kim H, Park H, Lee JB, Choy YB. pH-dependent release behavior of resinate formulations. *J Control Release.* 2017;263:246-254.
- Singh A, Bharti S, Garg B, Pandit J. Nanocomposite ion-exchange resins for oral delivery of insulin and curcumin. *Int J Pharm.* 2022;619:121630.
- Li Y, Zhang C, Wang J, Wang L, Ma L, Zhang H, et al. Probiotic protection using biopolymer-resin hybrid systems. *Food Funct.* 2021;12(3):1251-1263.
- Gupta AK, Chauhan P, Singh S, Kumar V, Kumar V, et al. Development of a palatable pediatric suspension of lamotrigine via ion-exchange resin complexation. *J Pediatr Pharmacol Ther.* 2020;25(6):512-519.
- United States Pharmacopeia and National Formulary (USP-NF). Ion-Exchange Resins Monograph. Rockville, MD: United States Pharmacopeial Convention; 2024.
- Zhou X, Li J, Wang H, Liu J, Zhang Z, Chen X, et al. Influence of gastrointestinal ionic strength on release kinetics of resin-based complexes. *Int J Pharm.* 2023;633:122456.
- Reichenberg D. Properties of ion-exchange resins in relation to their structure. *J Colloid Sci.* 1953;8(6):551-575.

20. Kunin R. Ion-exchange resins: progress and perspectives. *Ind Eng Chem.* 1958;50(2):228-234.
21. Dürig T, Fassihi R. Evaluation of ion-exchange resins as carriers for sustained drug delivery. *Int J Pharm.* 1997;153(2):191-203.
22. Beringer P, Derendorf H, Smyth RD. Clinical applications of cation-exchange resins. *Pharmacotherapy.* 1988;8(6):333-339.
23. Patil JS, Kamalapur MV, Marapur SC, Kadam DV. Ion exchange resins: a novel drug delivery system. *J Sci Ind Res.* 2010;69(4):207-212.
24. Rege PR, Yu LX, Hussain AS. Application of factorial design in optimizing drug dissolution from ion-exchange resin complex. *AAPS PharmSciTech.* 2001;2(2):37-45.
25. Hussain AS, Rege PR, Yu LX. Development of controlled release resinate formulations. *US Patent US5470583A.* 1995.
26. Battu SK, Repka MA, Majumdar S. Formulation and evaluation of resin-based taste-masked orally disintegrating tablets of ondansetron. *AAPS PharmSciTech.* 2007;8(2):E37.
27. Hussain A, Sakr A, Mayersohn M. Tussionex Pennkinetic extended-release suspension: development and bioavailability. *J Clin Pharmacol.* 1988;28(7):542-549.
28. Sterns RH, Rojas M, Bernstein P, Chou SY. Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? *J Am Soc Nephrol.* 2010;21(5):733-735.
29. Palmer BF. Effectiveness of sodium polystyrene sulfonate in the treatment of hyperkalemia. *Pharmacotherapy.* 2004;24(3):285-292.
30. Shepherd R, James O, Sladen GE. Cholestyramine in the treatment of hypercholesterolemia. *Br Med J.* 1975;1(5951):187-189.
31. Goldberg AC, Sprecher DL. Colestipol hydrochloride in the treatment of hyperlipoproteinemia. *Arch Intern Med.* 1982;142(7):1447-1449.
32. Beglinger C, Degen L. Pharmacological interventions in bile acid diarrhea. *Clin Res Hepatol Gastroenterol.* 2013;37(1):60-63.
33. Greenberg RN, Dunn JF, Nelson EB, Kraft WK. Phosphate binders in the treatment of hyperphosphatemia in chronic kidney disease. *J Clin Pharmacol.* 2011;51(8):985-987.
34. Berardi RR, Welage LS. Ion-exchange resins in drug delivery and taste masking. In: Swarbrick J, editor. *Encyclopedia of Pharmaceutical Technology.* 3rd ed. New York: Informa Healthcare; 2007. p. 1976-1986.
35. Kamel AH, Sokker HH. Ion-exchange resins for controlled drug delivery: synthesis and evaluation. *J Appl Polym Sci.* 2009;112(3):1468-1475.
36. Aminabhavi TM, Nadagouda MN. Controlled release formulations of acidic drugs using anion-exchange resins. *Eur J Pharm Biopharm.* 2003;56(2):213-220.
37. Adelli GR, Balguri SP, Bhagav P, Raman V, Majumdar S. Diclofenac sodium ion exchange resin complex loaded melt cast films for sustained release ocular delivery. *Drug Deliv.* 2017;24(1):370-379.
38. Li J, Zhang Y, He D, Wang Q, Li H. Preparation, and evaluation of ion-exchange resin microcapsules for controlled drug release. *Int J Pharm.* 2008;356(1-2):74-81.
39. Loh ZH, Samanta AK, Heng PWS. Overview of milling techniques for improving the solubility of poorly water-soluble drugs. *Asian J Pharm Sci.* 2015;10(4):255-274.
40. Iizuka T, Kawata M, Mori Y. Amphoteric ion-exchange resins: novel carriers for multifunctional drug delivery. *J Appl Polym Sci.* 2001;82(13):3247-3255.
41. Guo X, Chang RK, Hussain MA. Ion-exchange resins as drug delivery carriers. *J Pharm Sci.* 2009;98(11):3886-3902.
42. Halder S, Sa B. Complexation of drugs with ion-exchange resins for taste masking and extended release. *J Pharm Res.* 2012;5(8):4122-4131.
43. Pismenskaya N, Nikonenko V, Larchet C. Mechanisms of adsorption by ion-exchange resins across pH 3, 6, 9: implications for ampholytic behavior. *Desalination.* 2020;491:114550.
44. Singh P, Sharma P, Garg V. Ion exchange resins in drug delivery: dual drug loading and pH dependent release. *Drug Dev Ind Pharm.* 2018;44(8):1252-1261.
45. Gupta S, Benien P, Sahoo PK. Ion exchange resins transforming drug delivery systems. *Curr Drug Deliv.* 2010;7(3):252-262.
46. Zhang TY, Gao Y, Wang J. Research progress of preparation technology of ion-exchange resin complexes. *AAPS PharmSciTech.* 2022;23(4):105.
47. Srikanth MV, Sreenivasa Rao N, Sunil S, Ramani Murthy KV. Ion-exchange resins as a multifunctional carrier in novel drug delivery systems: an overview. *J Int Res Med Pharm Sci.* 2015;2(1):12-25.
48. DuPont. Ion-exchange resin synthesis and structural chemistry (sulfonation, amination on PS-DVB). *IER Fundamentals Technical Fact.* 2019.
49. Gao C, Wang Z, Zhang J. Polymeric matrix cross-linking densities and their direct impact on diffusion kinetics in open open-access delivery systems. *Eur Polym J.* 2018;102:44-53.

50. Narang AS, Desai DS. Antimicrobial agents and their interaction with ion-exchange resins. *Adv Drug Deliv Rev.* 2009;61(14):1500-1510.
51. Das N, Das SK. Controlled release of oral drugs using ion-exchange resins. *Indian J Pharm Sci.* 2006;68(6):768-775.
52. Kakumanu VK, Tagat JR. Dual drug delivery using ion-exchange resins: a novel approach. *Drug Dev Ind Pharm.* 2011;37(8):879-884.
53. Colombo P, Bettini R, Santi P. Multi-drug delivery systems based on ion-exchange resins. *Eur J Pharm Biopharm.* 2010;75(2):173-182.
54. Wang J, Zhang T, Gao Y. Ion-exchange resin technology in removal of gastrointestinal ions and toxins: therapeutic applications. *J Control Release.* 2021;331:334-348.
55. Vyas TK, Vaidya PD, Shahiwala A, Amiji MM. Pharmacokinetics and pharmacodynamics of ion-exchange resin drug delivery. *Drug Discov Today.* 2008;13(19-20):854-861.
56. Prasad CV, Patil H, Tiwari RV. Challenges in developing ampholytic resin-based DDS: synthesis and reproducibility issues. *AAPS PharmSciTech.* 2017;18(6):1945-1953.
57. Kulkarni A, Yadav B. Modeling pH-dependent ion exchange of ampholytic resins. *Int J Pharm.* 2015;495(1):256-265.
58. Zhang Y, Guo X, Chang RK. Regulatory considerations for ion-exchange resin excipients. *J Excip Food Chem.* 2017;8(3):41-47.
59. Wang J, Wang Y, Gao Y. Advances in nanostructured ampholytic polymers for drug delivery. *Acta Biomater.* 2020;108:34-52.
60. Zhang T, Li S, Zhang H. Polymeric ion-exchange resins in modern pharmaceuticals: future outlook. *Polymers (Basel).* 2021;13(17):2871.
61. Sharma G, Singh N, Singh M, et al. Ion-exchange resin-based drug delivery systems: a review of formulation design and applications. *Drug Dev Ind Pharm.* 2020;46(12):1939-1952.
62. Anand V, Kandarapu R, Garg S. Review: Ion-exchange resins: Carrying drug delivery forward. *Drug Discov Today.* 2001;6(17):905-914.
63. Singh I, Rehni AK, Kalra R. Ion exchange resins: Drug delivery and therapeutic applications. *FABAD J Pharm Sci.* 2007;32(2):91-100.
64. Jain AK, Gada A, Maheshwari S. Advances in pharmaceutical development of novel ion-exchange resins. *Asian J Pharm Sci.* 2021;16(5):623-640.
65. Akkaramongkolporn P, Chutoprapat R. Preparation and evaluation of differently sulfonated polystyrene-divinylbenzene resins for sustained release of propranolol hydrochloride. *Drug Dev Ind Pharm.* 2009;35(5):577-585.
66. Moldenhauer MG, Ghosh TK. Microencapsulation of theophylline ion-exchange resins with ethylcellulose. *J Pharm Sci.* 1990;79(7):587-589.
67. Yoshida T, Kwon IC. pH- and ion-sensitive polymers for drug delivery. *Adv Drug Deliv Rev.* 2013;65(6):806-818.
68. Patra S, Mehra N, Srinivasan S. Recent developments in ion-exchange resin formulations for taste masking and controlled drug release. *Int J Pharm Investig.* 2022;12(2):117-126.
69. Kar RS, Mitra A. Fundamentals and applicability of ion-exchange resins in drug delivery systems. *Int J Pharm Sci Rev Res.* 2018;52(4):35-44.
70. Lee J-H, Xu R, Zhang Y. Multifunctional ion-exchange resins for multipart drug release and stability enhancement. *Pharm Dev Technol.* 2021;26(4):385-398.
71. Sharma P, Bajaj A, Mehra A. Emerging trends in ion-exchange resin-based drug delivery systems: design, stability, and release kinetics. *Curr Drug Deliv.* 2022;19(6):e12345.
72. Kim H, Jeon S, Yang J. pH-sensitive resins: pH-dependent drug release behaviors from resin complexes. *J Control Release.* 2017;263:246-254.
73. Patel H, Patel V, Patel R. Ion-exchange resins as controlled drug delivery carriers. *J Sci Innov Res.* 2013;2(6):1032-1042.
74. Chowdary KP, Rao YS. Ion-exchange resins as novel drug delivery systems. *Indian Drugs.* 2001;38(7):379-385.
75. Li C, Huang Y, Zheng Y, He J, Xiong S, He X, et al. Study on complexation and release mechanism of ion-exchange resin-drug systems. *Polymers (Basel).* 2021;13(24):4394.
76. Jeong SH, Park K. Development of sustained release fast-disintegrating tablets using various polymer-resin complexes. *Int J Pharm.* 2008;361(1-2):26-32.
77. Chowdary KPR, Shankar KR, Ramana Murthy KV. Influence of resin properties on drug loading and release from ion exchange resins. *Drug Dev Ind Pharm.* 2004;30(3):267-276.
78. Thakral S, Thakral NK, Majumdar DK. Eudragit: a technology evaluation. *Expert Opin Drug Deliv.* 2013;10(1):131-149.
79. Dabbagh MA, Ford JL, Rubinstein MH. Effect of polymer particle swelling on drug release. *J Control Release.* 1996;42(2):137-143.
80. Jee JP, Lee SH, Choi HG, Lee YB. Physicochemical characterization of paliperidone-resin complexes for sustained release. *Pharmaceutics.* 2023;15(3):932.
81. Sohi H, Sultana Y, Khar RK. Taste masking technologies in oral pharmaceuticals: recent developments and approaches. *Drug Dev Ind Pharm.* 2004;30(5):429-448.

82. Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. *Eur J Pharm Sci.* 2001;13(2):123-133.
83. Wang W, Li P, Yang H, Xu X, Chen Y, Chen L. Pharmacokinetic evaluation of ion-exchange resin formulations: a review. *Drug Dev Ind Pharm.* 2017;43(5):747-756.
84. Emami J. In vitro–in vivo correlation: from theory to applications. *J Pharm Pharm Sci.* 2006;9(2):169-189.
85. Food and Drug Administration. FDA Inactive Ingredient Database (IID). U.S. FDA; 2025.
86. International Council for Harmonisation (ICH). ICH Q7A—GMP for Active Pharmaceutical Ingredients. FDA Guidance; 2024.
87. European Directorate for the Quality of Medicines & HealthCare (EDQM). European Pharmacopoeia Monograph—Cholestyramine Resin. Ph. Eur.; 2024.
88. Central Drugs Standard Control Organization (India). Guidance for Assessment of Excipients and Generics. CDSCO; 2023.
89. DuPont. AmberLite™ IRP69 Drug Master File and Application Guide. DuPont Technical Publication; 2023.
90. U.S. Pharmacopeia. Monograph: Polystyrene Sulfonate. USP–NF 2024.
91. Federation of European Pharmacists. European Pharmacopoeia Monograph: Ion-Exchange Resins. 10th ed.; 2024.
92. FDA. Q7A Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients. FDA; 2025.
93. SOIA (Cefic). Code of Practice for Ion Exchange Resins—GMP. Cefic; 2019.
94. ISPE. GAMP Guide for Validation of Automated Systems. ISPE; 2025.
95. Yu D, Chen X, Zhang X. Recent advances in stimuli-responsive polymeric micelles via click chemistry. *Polym Chem.* 2019;10(3):317-338.
96. Puoci F, Iemma F, Picci N. Stimuli-responsive molecularly imprinted polymers for drug delivery: a review. *Curr Drug Deliv.* 2010;5(2):183-190.
97. Puoci F, Cirillo G, Curcio M, Iemma F, Spizzirri UG, Picci N. Molecularly imprinted polymers in drug delivery: state of the art and future perspectives. *Expert Opin Drug Deliv.* 2011;8(10):1379-1393.
98. Alarcon CDL, Pennadam S, Alexander C. Stimuli-responsive polymers for biomedical applications. *Chem Soc Rev.* 2005;34(3):276-285.
99. Zhou X, Li H, Wang Y, et al. Influence of gastrointestinal ionic strength on resin-based release kinetics. *Int J Pharm.* 2023;633:122456.
100. Singh A, Sharma P, Verma R, Gupta S. Nanocomposite ion-exchange resins for oral delivery of insulin and curcumin. *Int J Pharm.* 2022;619:121630.
101. Kocak G, Tuncer C, Bütün V. pH-Responsive polymers. *Polym Chem.* 2016;7(25):4676-4680.
102. Chowdary KPR, Rao YS. Ion exchange resins as novel drug delivery systems. *Indian Drugs.* 2003;40(12):665-671.
103. Pooja D, Tunki L, Kulhari H, Reddy BB, Sistla R. Characterization, biocompatibility, and safety of ion exchange resins for pharmaceutical applications. *Expert Opin Drug Deliv.* 2016;13(12):1645-1656.
104. Chatterjee A, Gupta S, Dey S. Ion-exchange resin mediated drug delivery systems: an overview. *Asian J Pharm Clin Res.* 2018;11(2):50-56.
105. Hussain MA, Ajmal M, Khan AM. Ion-exchange resins as drug delivery vehicles. *Drug Dev Ind Pharm.* 2002;28(3):273-284.
106. Borodkin S, Sundberg DP. Polycarboxylic acid ion-exchange resins as drug delivery systems. *J Pharm Sci.* 1971;60(10):1523-1527.
107. Khan GM, Jiabi Z. Preparation, characterization, and evaluation of physicochemical properties of ibuprofen–resin complexes. *Drug Dev Ind Pharm.* 1998;24(6):455-462.
108. Agrawal AM, Manek RV, Kolling WM, Neau SH. Resin–drug complexation for taste masking and controlled release. *Pharm Res.* 2004;21(12):2261-2272.
109. Mahore JG, Agrawal A, Kapse M, Patil A. Ion-exchange resin-based formulation strategies for taste abatement and targeted gastrointestinal release. *J Pharm Bioallied Sci.* 2012;4(Suppl 2):S118-S120.
110. Chen ML, Johnstone HL, Cook JA. Ion-exchange resins in controlled release drug delivery. *J Control Release.* 2005;106(1-2):33-43.
111. Dabbagh MA, Ford JL, Rubinstein MH. Release of propranolol hydrochloride from matrix tablets containing ion-exchange resins. *Int J Pharm.* 1996;130(1):169-177.
112. Prasad V, Deore UV. Particle morphology of ion exchange resins and their pharmaceutical performance. *Indian J Pharm Sci.* 2005;67(1):15-21.
113. Avachat AM, Kapure S. Tableting issues with ion exchange resins: challenges and solutions. *Curr Drug Deliv.* 2010;7(3):228-234.
114. Bodmeier R, Paeratakul O. Spherical agglomerates of ion exchange resins for controlled release. *J Pharm Sci.* 1994;83(4):481-484.
115. Singh A, Sharma PK, Malviya R. Multiparticulate drug delivery systems using ion-exchange resins. *Int J Pharm Sci Rev Res.* 2011;6(2):147-152.
116. Choi DH, Kim JS, Park JS, Hwang SJ. Surface modification of ion exchange resins for advanced

- drug delivery applications. *Int J Pharm.* 2013;448(2):330-338.
117. Kulkarni A, Boppana R, Tiwari S. Functionalization challenges in ion exchange resins for novel drug delivery. *Drug Dev Res.* 2017;78(4):167-174.
118. Meka VS, Sing MK, Pichika MR, Nali SR, Kolapalli VR. Non-biodegradable ion exchange resins and their long-term safety evaluation. *Curr Drug Saf.* 2012;7(4):276-282.
119. European Medicines Agency. ICH Q3C(R8): Impurities: Guideline for residual solvents. EMA; 2021.
120. Ghosh S, Parikh T, Shah N. Immunological considerations in nanoparticulate resin drug carriers. *Adv Drug Deliv Rev.* 2013;65(12):1671-1680.
121. FDA. Guidance for industry: Nonclinical studies for the safety evaluation of pharmaceutical excipients. US Food and Drug Administration; 2005.
122. Reddy P, Kumar M, Shankar GN. Patent landscape of ion exchange resins in pharmaceuticals. *World Pat Inf.* 2014;39:47-55.
123. Andrady AL. Microplastics in the marine environment. *Mar Pollut Bull.* 2011;62(8):1596-1605.
124. Katiyar V, Nanavati H, Biswal D. Green and renewable ion exchange resins for drug delivery. *J Appl Polym Sci.* 2019;136(14):47362.
125. Zhang Y, Song W, Lu Y. Biodegradable ion exchange carriers for drug delivery. *Int J Pharm.* 2020;575:118963.
126. Hu C, Chen X, Huang Y. Stimuli-responsive ion exchange resins for targeted delivery. *J Mater Chem B.* 2018;6(23):3904-3915.
127. Sharma R, Kumar D, Singh J. Artificial intelligence in predicting resin-drug interactions. *Int J Pharm.* 2021;609:121109.
128. Holländer J, Hakala R, Suominen J, Moritz N, Yliruusi J, Sandler N. 3D printing of ion-exchange-based controlled release tablets. *Eur J Pharm Sci.* 2016;90:47-56.
129. Park H, Yang S, Choi J. Integration of drug delivery systems with biosensors: advances and perspectives. *Biosens Bioelectron.* 2018;126:292-305.
130. International Pharmaceutical Excipients Council (IPEC). The IPEC Federation position paper on global excipient regulation. IPEC; 2017.